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ABSTRACT
Scalable Bio-production of High Value Products in Bacteria
by
Yukie Kawasaki, Doctor of Philosophy
Utah State University, 2015
Major Professor: Dr. Jon Y. Takemoto
Department: Biology
Biliverdin IXα is a green bile pigment produced by enzymatic cleavage of a
tetrapyrrole ring of heme by heme oxygenase. While biliverdin IXα is emerging as an
effective cytoprotectant, the conventional method for producing biliverdin IXα by
chemical conversion of animal bile is not suitable for large scale production. A novel
scalable production method was pursued via bacterial fermentation. Recombinant
Escherichia coli strains were obtained by sequence optimization and plasmid
transformation of a cyanobacterial heme oxygenase gene. Further strain development
was done by plasmid overexpression of a native E. coli flavodoxin gene as a possible
electron donor for heterogeneous heme oxygenase. The resulting strains were grown in a
fed-batch culture system optimized for biliverdin IXα production.
Syringomycin E is a lipodepsinonapeptide produced by certain strains of
Pseudomonas syringae pv. syringae by nonribosomal peptide synthesis. Though
syringomycin E had been considered a phytotoxin in the past, recent research results
indicate that syringomycin E is a natural fungicide that is not toxic to animals and plants.
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Syringomycin E is a potential fungicide especially for use in the organic agriculture
sector. New strains of P. syringae pv. syringae were isolated through ultraviolet
mutagenesis and screenings for enhanced capability to produce syringomycin E
especially under agitated conditions. Fermentative production was conducted in a newly
formulated medium and the product was purified through a large scale chromatography
system using organic-compatible solvents. Purified syringomycin E was tested on
cucumber seeds to examine its antifungal activity against a soil-borne pathogen Pythium
ultimum. Syringomycin E was able to inhibit Pythium infection and protected seeds and
seedlings without developing disease symptoms.
This dissertation research showed scalable production of two natural products,
biliverdin IXα and syringomycin E in bacterial platforms. Strain development by gene
recombination and mutation was done to obtain bacterial strains capable of
overproducing desired metabolites. The resulting strains were grown in fermenters to
maximize the yields under agitated conditions. Monitoring growth parameters and
medium modifications were critical to achieve large scale production.
(134 pages)
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PUBLIC ABSTRACT
Scalable Bio-production of High Value Products in Bacteria
Yukie Kawasaki
Natural products are structurally and chemically diverse bioactive compounds
produced by living organisms. The complex structures of natural products are often
difficult to duplicate synthetically and thus industrial production of natural products most
often depends on use of the host organisms. In this dissertation research, scalable
production of natural products was pursued in bacterial platforms.
Biliverdin IXα is a natural anti-inflammatory compound which is emerging as a
potent cytoprotectant in the medical field. Syringomycin E is a natural fungicide
expected to be an effective agrofungicide in organic farming. Both biliverdin IXα and
syringomycin E have limited supplies in the market. Genetic modification and mutation
were performed to obtain bacterial strains capable of overproducing biliverdin IXα or
syringomycin E. The resulting strains were grown in fermenters under optimized growth
conditions for large scale production.
This research was conducted in the Department of Biology and Synthetic
Bioproduct Institute at Utah State University. Novel production methods of two different
natural products, biliverdin IXα and syringomycin E, were developed using bacteria as
manufacturing platforms.
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CHAPTER 1

INTRODUCTION
Background
Natural products are compounds or substances derived from living organisms (47).
Antibiotics, surfactants, hormones, enzymes, proteins, toxins and other functional
molecules are synthesized to promote the survival of the producing organisms.
Historically, natural products had been the major source of drugs on the market (24, 48,
63, 91). Though the use of synthetic chemicals has recently emerged, more than half of
all commercial drugs are still natural products or compounds based on natural products
(14, 34, 79, 124). Because of the complex structures of natural products (e.g., multiple
chiral centers and labile connectivity), it is often difficult to establish economical
chemical synthesis methods for their large scale production. Industrial production of
natural products most often depends on use of the original host organisms (132).
To supply industrial quantities, fermentation methods have been developed for
production of natural products (4, 29, 92, 96). The original definition of “fermentation”
is “anaerobic energy-yielding metabolism of carbon sources in which organic molecules
are involved as the final electron acceptors”. Another definition for this term is “any
process in which organisms are grown, especially on a large scale, even if the final
electron acceptor is not organic molecules and the growth is not carried out under
anaerobic conditions” (86). The latter definition is commonly used in industrial
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microbiology where large scale production of various useful natural products is pursued
using yeasts and bacteria as biocatalysts.
In nature, microbes usually produce natural products in small amounts, just
enough to satisfy their needs. For large scale microbial production of natural products,
improvement of the producer strains, so-called strain development, is required to enhance
desired metabolisms (1, 28, 90). Gene recombination is one approach to strain
development which combines pre-existing genetic traits into new combinations (50, 100).
Recent advances in recombinant DNA technologies allow isolation, cloning, synthesis,
and insertion of target genes in innate hosts or in surrogate organisms for gene
recombination. Mutation is another approach which involves mutagenesis (e.g., chemical
and radiation mutation) and selection of strains for desired metabolic activities (99). This
is a classic technique and efficient approach for strain development in a short period of
time.
As the results of strain development by gene recombination and mutation,
microbial strains can be obtained for overproduction of natural products. Next, a scaleup process of the production by the resulting strains from laboratory scale to industrial
scale is important (103). While screening of microbial strains generally performed in
shake flasks or tubes, industrial production of natural products are usually conducted in
large capacity fermenters. Oxygen transfer rates, agitation efficiencies, and hydraulic
pressures are highly affected by the size of culture broth (33, 103). Temperature, pH,
dissolved oxygen level, agitation, aeration, air flow, and nutrient concentrations need to
be monitored to have repeatable high-titer production in fermenters.
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In this research, attempts were made to enhance large scale production of two
natural products, biliverdin IXα and syringomycin E (SRE), by strain development and
fermentative growth of the resulting strains.
Biliverdin IXα
Heme degradation by heme oxygenase
Hemeproteins are metalloproteins containing heme, iron protoporphyrin IX, as the
prosthetic group. Electron transfer (41, 42), gas transfer (6, 18, 58), substrate oxidation
(88, 109), storage and transportation of metal irons (3, 20), ligand sensing (71, 123), and
other important physiological tasks are conducted by hemeproteins under aerobic
conditions. Despite their critical roles, senescent hemeproteins release pro-oxidant heme
which mediates formation of oxygen free radicals and lipid peroxidation (16). In
animals, pathological states such as sickled disease, ischemia reperfusions, and malaria
induce severe hemolysis and myolysis result in high levels of free heme leading to organ,
tissue, and cellular injuries (57, 68).
Heme oxygenase (HO, EC; 1.14.99.3) is primarily responsible for detoxifying
cytotoxic free heme. There are two HO isozymes, stress-inducible HO1 concentrated in
tissues of spleen and liver, and constitutive HO2 concentrated in neural tissues (30, 31,
128). HO cleaves the tetrapyrrole ring of heme at the α-methene bridge and forms
equimolar amounts of biliverdin IXα, Fe2+, and carbon monoxide (Fig. 1-1) (62, 68, 75,
131). Biliverdin IXα is a green bile pigment and subsequently converted into bilirubin
IXα, a yellow pigment known to cause hyperbilirubinemia, by biliverdin reductase (EC:
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1.3.1.24) of phagocytic cells (7, 94, 98). Bilirubin IXα is highly hydrophobic and binds
to albumin for circulation and transportation to the liver, where bilirubin IXα-albumin
bond is detached and then bilirubin IXα-glucuronic acid complex is formed for excretion
from the body in bile and feces (37, 69). While biliverdin IXα is the final product of
heme degradation in lower vertebrates, the conversion of biliverdin IXα into bilirubin
IXα is an immediate reaction and biliverdin IXα is hardly detected in mammals.
On the other hand, HO1 has a critical role in the synthesis of light harvesting and
light sensing apparatus in cyanobacteria (8, 23), some algae (9, 21), and higher plants
(26, 107) since the product biliverdin IXα is the common precursor of bilichromes. In
cyanobacteria and red algae, biliverdin IXα is converted into phycobilins by bilin
reductases such as PcyA for light harvesting (8, 22). In higher plants, phytochromobilins,
chromophores of phytochromes which function in light signaling, are synthesized from
biliverdin IXα (119). Though many cyanobacteria possess the biliverdin reductase gene,
bilirubin IXα hardly detected in these phototrophic organisms. Biliverdin reductase is
considered to have a regulatory role in phycobiliprotein biosynthesis (55, 102).
Therapeutic effects of biliverdin IXα
Biliverdin reductase generates 250-300 mg bilirubin IXα per day in normal
human adults (11). Bilirubin IXα is highly hydrophobic and >99% of bilirubin IXα is
bound to albumin to become soluble in plasma, while unbound bilirubin IXα disrupts cell
or mitochondrial membranes to cause cell lysis or mitochondrial dysfunctions (15, 59).
Albumin-bound bilirubin IXα is reactive with peroxyl radicals and oxidized back to
biliverdin IXα which can be re-reduced to bilirubin IXα by biliverdin reductase on the
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external plasma membranes of macrophages and other cells (87). The biliverdin
IXα/bilirubin IXα redox cycle is an important antioxidative mechanism which can protect
cells from 10,000-fold excess of peroxyl radicals (7).
While biliverdin reductase is an important amplifier in the biliverdin IXα/bilirubin
IXα redox cycle, biliverdin IXα-activated biliverdin reductase also undergoes
phosphorylation on its cytoplasmic tail. The serine/threonine/tyrosine kinase activity
initiates signaling cascades leading to anti-inflammatory and anti-apoptic responses,
including secretion of anti-inflammatory cytokines such as interferon-10 (70, 127, 129).
Administration of biliverdin IXα, less toxic but more hydrophilic form than bilirubin IXα,
is reported to be effective against ischemia and reperfusion injuries (5, 35, 85), diabetes
(54, 117), lung injuries (66, 101), human immunodeficiency virus (84), and hepatitis
(134). Biliverdin IXα is emerging as a potent cytoprotectant in the medical field.
Production of biliverdin IXα
Though there are raising interests in biliverdin IXα as a therapeutic reagent,
scalable production methods of biliverdin IXα had not been well established. Recent
commercially available BV is predominantly prepared by chemical conversion of
bilirubin IXα extracted from animal bile (89). Bilirubin IXα is dehydrogenated with
FeCl3, benzoquinone or H2O2 under acidic conditions (81), or 2,3-dichloro-5,6dicyanobenzoquinone in dimethyl sulfoxide (80). These chemical reactions usually
generate trace amounts of non-bioactive biliverdin IIIα and XIIIα isomers, dimers, and
other contaminants. Purification of biliverdin IXα isomer from the product mixture is
difficult and gives low yields (49, 80–82).
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In genetic engineering, Escherichia coli has been employed as the host organism
for foreign gene transformation because of its favorable traits, quick growth, well studied
metabolisms, and easier genetic manipulations (116). Although certain pathogenic
strains of E. coli express HO to acquire iron from infected animal hosts, biliverdin IXα
production in wild-type strains has not been reported (114, 115). There are some reports
of heterogeneous HO1 expression in E. coli while the yields were not specified or low.
Ishikawa et al. first performed the expression of rat HO1 in E. coli (56). This animal
enzyme has a 23-amino acid non-polar tail at its C-terminus to bind to cellular
membranes and for exchange of electrons with membrane bound NADPH-cytochrome
P450 reductase (CPR) (23). Later, Wilks et al. reported that soluble rat HO1 truncated at
its C-terminus is also catalytically active in E. coli (130). The activity of HO1 is strongly
dependent on the presence of electron donors (62). Since CPR does not exist in E. coli,
there must be substitute redox partners for heterogeneous rat HO1. The Synechocystis sp.
PCC6803 HO1 has been also successfully expressed in E. coli (23). Unlike animal HO1,
bacterial HO1 is not membrane anchored and does not accept electrons well from CPR
(32). Cyanobacterial HO1 was considered as ferredoxin (Fd)/flavodoxin (Fld)-dependent
but the specific Fd or Fld that supports the enzymatic activity of HO1 is not yet known
(7).
The first scalable production of biliverdin IXα was reported by Chen et al. (19).
Strain development of E. coli strain BL21(DE3) was done by gene recombination. A
sequence encoding the ho1 gene from Synechocystis sp. PCC6803 was modified for
optimum expression in E. coli and transformed to obtain a recombinant E. coli strain

7
BL21(mHO1). The resulting strain was grown in fermenters with optimization of growth
parameters, such as carbon sources, resulting in biliverdin IXα yield up to an average of
23.5 mg·L-1 culture broth.
Effects of different carbon sources on E.
coli biliverdin IXα production
Carbohydrates are the most common energy sources of bacteria. Different
carbohydrates affect different levels of glycolytic intermediates and thus different signal
transduction processes (12, 74, 112). For example, glucose-lactose diauxie is a wellknown catabolic repression associated with the lac operon in E. coli (73). Concentrations
of glucose and lactose or synthetic analogs of lactose control the expression of genes.
Inducible gene expression systems such as the lac operon are commonly used in
recombinant DNA technologies and many expression vectors were constructed with them
(110).
E. coli can utilize various carbohydrates, whereas glucose is the most easily
accessible compound and often used in industrial fermentation of E. coli (40). However,
expressions of heterogeneous proteins are often influenced by the glucose concentration
of the medium broth. Medium optimization of carbon sources is necessary to maximize
the production of target proteins or metabolites. Glucose, sucrose, lactose, mannitol,
sorbitol and other sugars can be tested individually or in combinations. In the study of
Chen et al. (19), recombinant E. coli strains BL21(HO1) and BL(mHO1) were obtained
using a lac operon vector system. Optimization of carbon source was performed as a part
of this dissertation study to enhance biliverdin IXα production.
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Redox partner of enzymatic activity of
heme oxygenase
The enzymatic activity of HO1 is strongly dependent on electrons derived from
NADPH. In mammals, electron transfer from NADPH to HO1 is mediated by CPR
which consists of four structural domains, the flavin mononucleotide (FMN)-binding
domain, the connecting domain, the flavin adenine dinucleotide (FAD)-binding domain,
and the NADPH-binding domain, connected in sequence from the N- to C- temini (126).
The FMN-binding domain is similar to the structure of Fld, whereas the FAD-binding
domain and NADPH-binding domain are similar to these of ferredoxin-NADP + reductase
(FNR). Electrons are transported from NADPH to CPR (first to the FAD prosthetic
group and then to the FMN prosthetic group) and from CPR to HO1 for heme
degradation (5, 7).
On the other hand, cyanobacterial HO1 uses Fd as the electron donor (23, 113).
Cyanobacterial HO1 does not have an anchor tail on its C-terminus while amino acid
residues around the heme binding site are highly conserved (e.g., 57% similarities
between human HO1 and Synechocystis PCC 6803 HO1). Though catalytic activity of
cyanobacterial HO1 was reported with CPR as the electron donor, its narrower heme/electron donor-binding site prefers plant-type 2Fe-2S Fd (~10 kDa) rather than CPR
(~77 kDa) (113).

The electron flow is expected to be from NADPH to FNR (FAD

prosthetic group), from FNR to Fd, and from Fd to HO1 (23, 67).
Replacement of Fd with Fld is reported under environmental stress (13, 39, 72).
Fld is a small soluble flavoprotein (14-23 kDa) which has a non-covalently bound FMN
molecule as a prosthetic group instead of an iron-sulfur cluster. Fld is isofunctional to Fd
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and able to mediate NADP+ reduction via FNR (72). In general, Fd is used as a major
electron carrier while Fld is induced under adverse conditions. For instance,
cyanobacteria express Fld under iron-deficient conditions to replace Fd (13, 39). Few
organisms like E. coli and Helicobacter pylori are known to require Fld as a specific
electron carrier for their survival (38, 51, 95). In recombinant E. coli strain
BL21(mHO1) (19), the redox partner of heterogeneous mHO1 is unknown. However, it
is predicted that the electron is provided from NADPH to FNR, from FNR to Fd/Fld, and
from Fd/Fld to mHO1.
Syringomycin E
Disease controls in organic agriculture
The Federal Organic Foods Production Act of 1990 was a milestone for organic
farming in the United States. This act established standards for producing and marketing
organically produced commodities. In 2014, the sales of organic qualified products
reached US $39.1 billion (122). The organic farming industry is a fast-growing sector of
the US agriculture with rising concerns on environmental protection and food safety (93).
However, with such an accelerated growth, disease control is emerging as a huge
problem. Applications of synthetic chemicals are not allowed in organic farming
whereas adaption of chemical compounds greatly contributes to the success of
conventional agriculture. Demands for organic-compatible pesticides consisting of
natural products, naturally occurring microbes, and mined minerals (121) are increasing.
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Fungi and fungal-like organisms are the major cause of plant diseases (64). They
produce thick-walled spores resistant to desiccation and other extreme environmental
conditions. Spores can survive for many years and it is difficult to remove them from
soil. Soil-borne pathogens such as Fusarium, Rhizoctonia, Pythium, and Phytophthora
are known to cause damping-off diseases that can affect various vegetable seeds and
seedlings (65). The outbreak of damping-off disease results in significant loss of yield
and quality of produces. Seed treatment is a common approach to prevent damping-off
disease and most commercially available seeds are treated with synthetic fungicides (17,
53, 60, 77, 97, 106, 120, 125). However, exclusion of synthetic chemicals limits the
choice of disease control in organic farming. Most organic seeds in the market remain
untreated. Though physical treatments (e.g., temperature and radiation treatments) are
available, they possibly cause seed damages (43). There is a demand for organiccompatible fungicides for seed treatments.
Syringomycin E as a secondary
metabolite natural fungicide
Besides ribosomal peptides, microorganisms synthesize small peptides by using
multifunctional enzymes of 100–1700 kDa , the so-called nonribosomal peptide
synthetases which utilize the multiple-carrier thiotemplate mechanism (32, 78, 105).
Nonribosomal peptides have structural diversities, like branched/cyclic parts and nonproteinogenic amino acids, and they thus have diverse bioactivities. Certain strains of
Pseudomonas syringae pv. syringae produces syringomycin E (SRE) (Fig. 1-2) via
nonribosomal peptide synthesis (108). SRE consists of a hydrophobic 2-
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hydroxydodecanoate tail and a hydrophilic nine-amino acid peptide ring (Fig. 1-2). The
positive charge of the peptide ring gives SRE a high affinity for binding to the negatively
charged sphingolipids on fungal plasma membrane (45, 111). The amphiphilic structure
of SRE inserts into the target membrane to form voltage-gated ion channels slightly
selective for anions (2, 52, 76). The resultant ionic imbalance caused by ion fluxes is
lethal to fungi. Antifungal activity of SRE has been reported against phytopathogenic
fungi and fungal-like organisms such as Fusarium, Rhizoctonia, and Phythium species
(10, 27, 61). As a secondary metabolite natural product with a potent antifungal activity,
SRE is a potential fungicide for disease control applications in organic farming (118).
Production of syringomycin E
For applications in agriculture, a scalable production method will be required to
supply a large quantity of SRE. It is difficult to meet this goal with the current still batch
culture preparation method, incubation of P. syringae pv. syringae B301D in potato

dextrose broth supplemented with 0.4% of casamino acids at 28 ℃ for 10 days without
shaking (44, 133). Though genetic modification is a common approach to obtain
enhanced producer strains, genetically modified organisms are not allowed in organic
food production (25, 46). Also, the SRE gene cluster of P. syringae pv. syringe
encompass as approximately 55 kb (104) and handlings of large gene clusters usually
entail difficulties (36). In this study, strain development of P. syringae pv. syringae was
performed via ultraviolet (UV) radiation mutagenesis regarding the USDA organic
standards (83). Strains were selected for their enhanced capability to produce SRE,
especially in agitated conditions. Then optimization of fermentation parameters was
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conducted to obtain organic-compatible SRE to be tested as a seed protectant fungicide
against Pythium infection.
Goals of This Study
Many microorganisms are capable to produce bioactive natural products. Though
these compounds are highly valuable to us, the amounts of product in wild-type strains
are usually limited. The main goal of this dissertation research was to perform scalable
production of high-value natural products, biliverdin IXα and SRE. Biliverdin IXα is an
emerging cytoprotectant in human therapeutics and SRE is a possible fungicide in
organic agriculture. Though they have potent bioactivities, large scale production
protocols of biliverdin IXα and SRE have not well established. As is common in recent
industrial microbiology, scalable production of biliverdin IXα and SRE was pursued by
microbial strain development and fermentation optimization for the resulting strains.
Bacterial strains capable of overproducing biliverdin IXα and SRE were obtained by gene
recombination and mutagenesis, respectively. For quick production of biliverdin IXα
with easier gene manipulations, modified cyanobacterial HO1 was plasmid transformed
into E. coli (Chapter 2). To improve enzymatic activity of the heterogeneous gene,
possible electron donors were overexpressed in the transformed cells (Chapter 3). For
production of SRE as an organic-compatible agrofungicide, enhanced SRE producer
strains of P. syringae pv. syringae were obtained by UV mutagenesis (Chapter 4).
Productions of biliverdin IXα and SRE with the resulting strains were conducted in
fermenters with optimization of growth parameters such as carbon sources.
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FIG. 1-1. Heme degradation by HO and BV reductase. The three reactions shown in the
box are conducted by HO while the conversion of biliverdin IXα into bilirubin IXα is
conducted by biliverdin reductase.
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CHAPTER 2
*SCALABLE PRODUCTION OF BILIVERDIN IXα BY ESCHERICHIA COLI
Abstract
Background. Biliverdin IXα is produced when heme undergoes reductive ring
cleavage at the α-methene bridge catalyzed by heme oxygenase. It is subsequently
reduced by biliverdin reductase to bilirubin IXα which is a potent endogenous
antioxidant. Biliverdin IXα, through interaction with biliverdin reductase, also initiates
signaling pathways leading to anti-inflammatory responses and suppression of cellular
pro-inflammatory events. The use of biliverdin IXα as a cytoprotective therapeutic has
been suggested, but its clinical development and use is currently limited by insufficient
quantity, uncertain purity, and derivation from mammalian materials. To address these
limitations, methods to produce, recover and purify biliverdin IXα from bacterial cultures
of Escherichia coli were investigated and developed.
Results. Recombinant E. coli strains BL21(HO1) and BL21(mHO1) expressing
cyanobacterial heme oxygenase gene ho1 and a sequence modified version (mho1)
optimized for E. coli expression, respectively, were constructed and shown to produce
biliverdin IXα in batch and fed-batch bioreactor cultures. Strain BL21(mHO1) produced
roughly twice the amount of biliverdin IXα than did strain BL21(HO1). Lactose either
alone or in combination with glycerol supported consistent biliverdin IXα production by
*Published: Chen, D., J. D. Brown, Y. Kawasaki, J. Bommer, and J. Y. Takemoto. 2012.
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strain BL21(mHO1) (up to an average of 23.5 mg·L-1 culture) in fed-batch mode and
production by strain BL21(HO1) in batch-mode was scalable to 100 L bioreactor culture
volumes. Synthesis of the modified ho1 gene protein product was determined, and
identity of the enzyme reaction product as biliverdin IXα was confirmed by spectroscopic
and chromatographic analyses and its ability to serve as a substrate for human biliverdin
reductase A.
Conclusions. Methods for the scalable production, recovery, and purification of
biliverdin IXα by E. coli were developed based on expression of a cyanobacterial ho1
gene. The purity of the produced biliverdin IXα and its ability to serve as substrate for
human biliverdin reductase A suggest its potential as a clinically useful therapeutic.
Introduction
Biliverdin is a linear tetrapyrrole produced by ring cleavage of heme catalyzed by
the enzyme heme oxygenase (HO) (E.C.C.1.14.99.3) [1]. In animals, heme cleavage by
HO occurs selectively at the α-methene bridge to generate the most physiologically
relevant biliverdin IXα isomer. Hence, the term “biliverdin” typically refers specifically
to biliverdin IXα, and this usage is applied throughout in this paper. Biliverdin is best
known as a degradative intermediate associated with erythrocyte and hemoglobin
turnover. It is subsequently reduced via NADPH biliverdin reductase (E.C.C. 1.3.1.24)
to bilirubin IXα that in turn is consecutively bound to serum albumin and glucuronic acid
for excretion in bile. The overall process serves to eliminate heme, which is toxic when
accumulated.
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Bilirubin IXα is also known to associate with cell membranes where it quenches
the propagation of reactive oxygen species (ROS) [2, 3] conferring protection to
membrane lipids and proteins against oxidative damage. Thus, an additional function of
biliverdin is to serve as the immediate source of bilirubin IXα that in turn acts as a
cytoprotective antioxidant. It is not clear if biliverdin is oxidatively regenerated after
bilirubin IXα reacts with ROS [4–7]. Though bilirubin IXα is an effective ROS
quencher, biliverdin administered at tissue injury/inflammatory sites appears as effective
a cytoprotectant as bilirubin IXα [8–13]. Biliverdin’s effectiveness has been attributed to
its hydrophilicity and efficient conversion to bilirubin IXα [1]. In addition, biliverdin
interaction with biliverdin reductase signals the downstream production of antiinflammatory cytokine interferon-10 [14] and the nitrosylation-dependent inhibition of
pro-inflammatory TLR4 expression [15]. Thus, biliverdin, acting together with biliverdin
reductase, is increasingly recognized as a potential anti-inflammatory therapeutic agent
[3, 16–18]. Examples of its cytoprotective effects in animal models include those for
ischemia/reperfusion following liver [19] and small bowel [10] transplants, vascular
injury [20], endotoxic shock [21], vascular intimal hyperplasia [9], and nephropathy [8].
In addition, biliverdin has been reported to inhibit in vitro replication of hepatitis C [22]
and other viruses [23, 24] and to reverse parameters of type 2 diabetes in mice [25]. The
growing list of potential clinical applications for biliverdin suggests a future need for
high-quality preparations in ample quantity.
Biliverdin is also produced by microbes and plants [26–30]. In cyanobacteria, red
algae, and plants, it serves primarily (and perhaps solely) as precursor to photosensitive
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linear tetrapyrroles such as phycocyanobilin and phycoerythrobilin [31]. These in turn
serve as chromophores for cyanobacterial and red algal light-harvesting phycobiliprotein
complexes and the light-sensing receptor phytochrome [27, 32]. In these organisms,
biliverdin IXα is the predominant isomer produced via HO enzymes with sequence
homologies to mammalian HO1 [28, 33, 34].
To meet the projected pharmaceutical demand for biliverdin, high yield and low
cost methods that provide the IXα isomer in high purity and preferably from nonmammalian sources are needed. Currently, commercial biliverdin is predominantly
derived by chemical oxidation of bilirubin [35]. The source bilirubin (that occurs in
conjugated form) is extracted from mammalian bile under acidic conditions that generate
isomers (e.g. IIIα and XIIIα isoforms) and consequently lead to biliverdin preparations of
unsuitable purity (e.g. as low as 38% biliverdin IXα [36]). Reported non-mammalian
synthesis of biliverdin include Escherichia coli cultures expressing HO1 from rat [37, 38]
and cyanobacteria [39] and yeast cultures supplemented with hemoglobin [40]. In these
reports, the amounts of biliverdin produced are not documented or appear low.
Biliverdin extracted from salmon bile is reported [41], but the potential for scalable
production is not discussed.
Here, we report the use of E. coli to synthesize biliverdin and describe procedures
for the scalable production of the IXα isomer. This was achieved by sequence
optimization of the cyanobacterial ho1 gene for enhanced expression in E. coli and
development of growth culture parameters that promote biliverdin production.
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Materials and Methods
E. coli strains and vectors
One Shot® TOP10 Chemically Competent E. coli (Life Technologies, Carlsbad,
CA, USA) was used to construct the recombinant plasmids. BL21 Star™ (DE3)
Chemically Competent E. coli (Life Technologies, Carlsbad, CA) was used for
transformation and protein expression. Expression vector constructions were done with
pET101/D-TOPO® (Life Technologies, Carlsbad, CA) and pJexpress 401 (DNA2.0,
Menlo Park, CA).
Construction of expression vectors
pET101-HO. The heme oxygenase gene (ho1) of Synechocystis PCC6803 was
amplified by PCR of Biobrick gene part BBaI15008 (Registry of Standard Parts, The
BioBricks Foundation, http://biobricks.org/ webcite) using forward primer 5’-CACC
ATGAGTGTCAACTTAGCTTC-3’ and reverse primer 5’-CTAGCCTTCGGAGGT
GGCGA-3’ and cloned into pET101/D-TOPO® to generate plasmid vector pET101-HO1
(Figure 2-1.A) with expression under T7 lac promoter control according to instructions
provided by Life Technologies (Carlsbad, CA) (TOPO® Cloning Reaction Method). The
ho1 gene sequence was verified by DNA sequencing. The vector pET101-HO1 was
transformed into BL21 Star™ (DE3) Chemically Competent E. coli to give E. coli strain
BL21(HO1).
pJexpress401-mHO1. The ho1 gene sequence was codon optimized for
expression in E. coli using DNA2.0 Algorithms (DNA2.0, Inc., Menlo Park, CA) (Figure
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2-2). The coding sequence for hexahistidine was incorporated at the 5’ end to provide a
6× His tag at the N-terminus of the synthesized protein. The E.coli codon optimized gene
(mho1) was synthesized and inserted into plasmid vector pJexpress401 by DNA2.0 Inc.
(Menlo Park, CA). The resulting vector, pJexpress401-mHO1 (Figure 2-1.B), was
transformed into BL21 Star™ (DE3) Chemically Competent E. coli to give E. coli strain
BL21(mHO1).
Testing carbon sources for biliverdin production
Several carbon sources at different concentrations and in combination were
examined for capabilities to support growth and biliverdin synthesis by E. coli strains
BL21(HO1) and BL21(mHO1). Cultures were grown in 125 mL capacity Erlenmeyer
flasks on a New Brunswick G76 rotary incubator shaker (30°C, 200 rpm) in 50 mL
Luria-Bertani (LB) medium [42] with various single carbon sources that included sucrose
(1% wt·vol-1), mannitol (0.1, 1, 2, 5, 10 and 20% wt·vol -1), sorbitol (1, 5, 10 and 20%
wt·vol-1), lactose (1, 2.5, 5 and 10% wt·vol-1), succinate (2% (wt·vol-1), malate (2%) or
combinations of carbon sources that included mannitol (1% wt·vol -1) + glucose (1%
wt·vol-1), sucrose (1% wt·vol-1) + glucose (1% wt·vol-1), mannitol (1% wt·vol-1) +
sorbitol (2.5% wt·vol-1), or mannitol (5% wt·vol-1) + sorbitol (5% wt·vol-1). Ampicillin
or kanamycin (100 μg·mL-1) was used for selection, and isopropyl-βthiogalactopyranoside (IPTG) (0.5 mM) was added (at cell density with absorbance (1
cm) (A600) of ~0.5) as inducer except when lactose was the carbon source. Growth was
monitored at A600 and the culture color was recorded when stationary phase growth was
achieved (24 to 48 h). Biliverdin levels were estimated by absorbance spectroscopy
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using a mM extinction coefficient of 25 at 650 nm (1 cm light path length) using a
SpectraMax Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale,
CA).
Biliverdin production using bioreactor
batch cultures
For bioreactor inocula, E. coli strains BL21(HO1) and BL21(mHO1) were grown
in 50 mL of LB medium plus 100 μg·mL-1 ampicillin or kanamycin, respectively, in 250
mL capacity Erlenmeyer flasks with rotary shaking (225 rpm) at 37℃ to an A600 of 2 to 6
with LB medium as a blank control. Inoculum cultures (80 mL) were added to 2 L of
modified New Brunswick Scientific (NBS) medium [43] with 2% (wt·vol -1) lactose in
place of glucose or modified ZY medium [44] composed of per L: 2 g lactose, 2.2 g
glucose, 16 g glycerol, 15 g N-Z-Amine™ A or 10 g Hy Express System II (Sheffield™
Bio-Science, Norwich, NY), 10 g yeast extract (FisherScientific, Waltham, MA), 1 mL
2M MgSO4, 50 mL of 20× NP solution (66 g (NH4)2SO4, 136 g KH2PO4, 142 g Na2HPO4
in 1 L twice-distilled H2O), and 1 mL 1000× trace elements solution (50 mL of 1% HCl,
0.675 g FeCl3, 0.15 g CaCl2, 0.1 g MnCl2, 0.015 g ZnSO4, 0.023 g CoCl2, 0.015 g CuCl2,
0.023 g NiCl2, 0.025 g Na2MoO4, 0.007 g H3BO3 in distilled water to a final volume of
250 mL). Separately, 20× NP solution and 2 M MgSO 4 were autoclaved and 1000× trace
elements solution was filter-sterilized, and the solutions were added to complete the
preparation of modified ZY growth medium. Batch culture growth was conducted in a
New Brunswick Scientific BioFlo® 310 Controller bioreactor using BioCommand
software with a 5 L capacity vessel (New Brunswick Scientific Co., Endfield, CT). A
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dissolved O2 level of 40% was cascade controlled and monitored by gassing with O 2 (050%) and air (0.75-4 slpm). No antifoam was used. For fed-batch experiments, a 200
mL solution of 10% (wt·vol-1) glycerol, 2% (wt·vol-1) lactose, and with or without 5%
(wt·vol-1) peptone was continuously fed (8 mL·h-1·L-1) during exponential growth
beginning 4 h after inoculation. Cell culture absorbance (A 600) was approximately 10 at 4
h and 29 at 11 h after culture inoculation. Growth was terminated approximately 25 h
after inoculation. Green material (containing biliverdin) accumulated in foam above the
culture liquid surface and on the inner surfaces of the bioreactor vessel and in the foam
over-flow material that was siphoned into a flask outside the vessel. The pigmented
material was collected using methanol or distilled water as necessary and the pH of the
final suspension was lowered to 4.3 or 4.5, respectively, to promote biliverdin
precipitation. The recovered material was centrifuged at 7477×g for 6 min, and the
sedimented blue-green material was suspended in methanol. Non-sedimenting biliverdin
in aqueous fractions was recovered by readjusting the pH to 4.3 followed by recentrifugaton and suspension of the green pellet in methanol. The pooled methanolic
solutions were placed on a rotating shaker (225 rpm) at room temperature for 15 min.
The solution was centrifuged at 4500×g for 4 min to remove particles from solution.
Fresh methanol was added to the pellet, and the extraction repeated. The extraction is
further repeated with distilled methanol until the A 650 of a 1:10 dilution of the supernatant
fluid is less than 0.5. The amounts of biliverdin recovered were quantitated by HPLC
with comparisons to known amounts of authentic biliverdin IXα (Frontier Scientific, Inc.,
Logan, UT).
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Larger (100 L) batch cultures of E. coli strain BL21(HO1) were grown at 37°C
with NBS medium containing 2% (wt·vol-1) lactose in a B. Braun UE-100D bioreactor
(B. Braun Melsungen AG, Germany). Fed-batch mode was not used. E. coli strain
BL21(HO1) inoculum cultures (4 L) were grown overnight at 37°C in LB medium in
BioFlo® 310 bioreactors. Inoculum cultures (4 L) were added to 100 L growth medium
and growth was terminated 24 h following inoculation. Biliverdin was collected,
extracted and purified as described above for the 2 L bioreactor batch cultures.
HO identification and activity
HO cell extraction. Aliquots (48 to 400 mL) of bioreactor batch culture of E.
coli strain BL21(mHO1) were collected at 2, 5, 10, 15, and 2 h after inoculation,
centrifuged (4500×g, 5 min), and the supernatant liquid discarded. The sedimented cell
pellets were stored at −20°C. The cells were extracted, and proteins were recovered from
Ni-NTA columns using the QIAexpress® Ni-NTA fast Start Kit (QIAGEN, Valencia,
CA) according to procedures described in the kit manual.
SDS-PAGE. Twenty μL of each protein solution from Ni-NTA column
purification were added to 20 μL of SDS-PAGE sample buffer (Bio-Rad, Hercules, CA),
heated for 10 min with boiling water, and centrifuged briefly. Supernatant liquid aliquots
(30 μL) were loaded into wells of Bio-Rad Criterion Precast Gels and electrophoresed in
a Bio-Rad Criterion precast Gel System. The gel was stained using Bio-safe™
Coomassie G-250 (Bio-Rad, Hercules, CA). Precision Plus Protein Prestained Standards
(Bio-Rad Laboratories, Hercules, CA) was used for estimation of protein molecular size.
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Identification. Ni-NTA column purified protein samples were reduced and
alkylated with iodoacetamide. The resulting peptides were concentrated on a ZipTip
micropurification column and eluted onto an anchorchip target for analysis on a Bruker
Autoflex III MALDI TOF/TOF instrument (performed by Alphalyse, Inc., Palo Alto,
CA). The peptide mixture was analyzed in positive reflector mode for accurate peptide
mass determination. MALDI TOF/TOF analyses were performed on 8 separate peptides
for partial peptide sequencing. The MS and MS/MS spectra were combined and analyzed
using Mascot software and NCBI protein databases.
HO activity. Harvested E. coli strain BL21(mHO1) and BL21 StarTM (DE3) cells
were washed and suspended in assay buffer (50 mM Tris-HCl, pH 7.7, 10% wt·vol -1
glycerol) and 1 mM EDTA, and disrupted three times using a French press cell operated
at 18,000 psi. The lysate was centrifuged at 15,000×g, and the supernatant fraction was
used for HO activity assays similar to published procedures [28, 45]. The enzyme
reaction mixture (500 μL) contained assay buffer, 40 μM methemalbumin, 2.5 mM Tiron,
20 μg·mL-1 ferredoxin, 0.02 units of ferredoxin reductase (Sigma-Aldrich, St. Louis,
MO), and cell lysate (0.128 mg protein). The reaction was initiated with the addition of
0.2 mg of NADPH and the mixture was incubated at 37°C for 20 min in the dark. The
mixture was then extracted and esterified [46] and biliverdin dimethyl ester was
quantitated by HPLC using a Beckman C18 Ultrasphere column (4.6 mm×15 cm),
elution with methanol, and absorbance measurement at 380 nm.
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Biliverdin purification
Ammonium acetate (0.1 M, 1.5 L) was mixed with biliverdin in buffered
methanol (60% 0.1 M ammonium acetate/40% methanol, vol·vol -1, 1 L) and the mixture
was loaded onto a glass column (4.0 mm×300 mm) packed with C18 silica beads (125Å
pore, 55-105 μM diameter, Waters, Manchester, UK). The column was preconditioned
by sequential elution with 200 mL of methanol and 200 mL of buffered methanol. After
loading the sample, the column was washed with 100 mL buffered methanol solution.
Biliverdin was eluted with 30% 0.1 M ammonium acetate/70% MeOH (vol·vol -1)
solution and collected as material in a green band. To 25 mL of eluted biliverdin material
was gradually added 400 mL of 1 mM HCl with stirring. The solution was kept at −20°C
for 1 h and then centrifuged for 15 min at 11325×g at 4°C. The supernatant fluid was
removed, the biliverdin pellet was washed and suspended in 20 mL H 2O in a 50-mL
capacity plastic centrifuge tube and centrifuged for 15 min at 4500×g at 4°C. The
supernatant fluid was discarded, the biliverdin pellet was frozen at −80°C and then
freeze-dried using a FreeZone Plus Freeze Dry System (Labconco, Kansas City, MO).
Biliverdin characterization
Absorbance spectra. Absorbance spectra (300 and 800 nm) were obtained using
a SpectraMax Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale,
CA).
HPLC analysis. Biliverdin samples (20 μL were subjected to HPLC using a 4.6
mm×75 mm Symmetry® C18 column (Waters Co., Milford, MA) and a gradient of
solvent A: 99.9% H2O, 0.1% trifluoroacetic acid and solvent B: 99.9% methanol and
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0.1% trifluoroacetic acid. The elution gradient program was: 100% solvent A, 1 min; 060% solvent B, 1min; 60-100% solvent B, 8 min, 0-100% solvent A, 1 min; 100%
solvent A, 4 min with a flow rate of 1 mL·min -1 using a Waters Alliance HPLC (Waters
Co., Milford, MA).
Proton NMR analysis. NMR data was collected on a JEOL Eclipse 400MhZ
NMR (JEOL, Peabody, MA). Biliverdin samples were dissolved in DMSO-d6
(Cambridge Isotope Labs, Andover, MA).
LC-MS analysis. Biliverdin samples were analyzed on a NanoACQUITY UPLC
(Waters Co., Milford, MA) and a Q-Tof Primer tandem mass spectrometer (Waters Co.,
Milford, MA). Samples (3 μL) were introduced into a Symmetry® C18 trapping column
(180 μm×20 mm) with NanoACQUITY Sample Manager (Waters Co., Milford, MA)
washed with 99% solvent A and 1% solvent B for 3 min at 15 μL·min -1. Solvent A was
99.9% H2O, 0.1% formic acid and solvent B was 99.9% acetonitrile and 0.1% formic
acid. Chemicals were eluted from the trapping column over a BEH300 C4 column with a
40 min gradient (1-4% solvent B, 0.1 min; 4-98% solvent B, 19.9 min; 98-85% solvent B,
2 min; 85% solvent B, and 10 min, 85-1% solvent B, 8 min) at a flow rate of 0.8
μL·min-1. MS scan time was 1.0 sec.
NADPH biliverdin reductase activity
The enzymatic conversion of biliverdin to bilirubin was measured using the
Biliverdin Reductase Assay Kit (Sigma-Aldrich, St. Louis, MO). One mg of biliverdin
producd by strain E. coli strain BL21(mHO1) was dissolved in 2 mL methanol, and 0.2
mL was mixed with 1 mL of the kit assay buffer. The kit-supplied recombinant human
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biliverdin reductase A enzyme was suspended in 800 μL water, and 160 μL of the
enzyme suspension was added to 480 μL of assay buffer. Biliverdin-containing kit assay
buffer (50 μL), biliverdin reductase solution (200 μL), and NADPH solution (0.24
mg·mL-1 NADPH in assay buffer, 750 μL) were combined and the absorbance spectrum
between 300-800 nm was measured at 0, 15, 30, 45, 60, 90, 145, 240 and 360 min using a
SpectraMax Plus384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale,
CA).
Results and Discussion
Effect of carbon source on biliverdin production
Several potential carbon sources, alone and in combination, were examined for
their abilities to support biliverdin production by E. coli strains BL21(HO1) and
BL21(mHO1) growing in LB medium (Table 2-1). Lactose at 2 and 2.5% (wt·vol -1)
alone or in combination with D-glucose yielded green cultures containing 2 to 4 mg·L -1
biliverdin without IPTG addition. E. coli strain BL21(HO1) cultures grown with Dmannitol (alone or in combination with glucose or sorbitol) also yielded green cultures
whereas other carbon compounds and combinations (Table 2-1) yielded brown or yellowgreen and pale green cultures containing <0.2 and <2 mg·L-1 biliverdin, respectively.
Similarly, E. coli strain BL21(mHO1) produced enhanced amounts of biliverdin with
lactose alone or in combination with D-glucose. These results show that certain
carbohydrates and particularly lactose (2 to 2.5% wt·vol-1), alone or in combination with
D-glucose, and D-mannitol (2 to 5% wt·vol-1) support higher levels of biliverdin
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production by E. coli strains BL21(HO1) and BL21(mHO1) growing in LB medium as
compared to other carbon sources. With lactose, the addition of IPTG was not required
for enhanced biliverdin production offering a practical and economic advantage for largescale, commercial production of biliverdin.
Bioreactor batch culture production of biliverdin
Based on observations that lactose enhanced biliverdin production, modified ZY
medium containing 2% wt·vol-1 lactose was used to grow E. coli strains BL21(HO1) and
BL21(mHO1) in 2 L volumes in a New Brunswick Scientific BioFlo ® 310 Controller
bioreactor. Consistent biliverdin production was achieved with 40% dissolved O 2,
agitation between 280 and 500 rpm, and continuous feeding of lactose (2% wt·vol -1) and
glycerol (10% wt·vol-1) in fed-batch mode initiated 4 h after culture inoculation
(exponential growth phase). Biliverdin was visible as and collected in green material that
accumulated in the foam above the culture liquid surface (Figure 2-3). Biliverdin was
identified and quantitated by HPLC analyses of the collected material. E. coli strains
BL21(HO1) and E. coli BL21(mHO1) produced between 2.5 and 5 mg (n=3, average 3.3
mg) and between 5.3 to 7.5 mg (n=9, average 6.4 mg) of biliverdin, respectively, per L of
culture. Therefore, E. coli strain BL21(mHO1) produced nearly twice the amount of
biliverdin than E.coli strain BL21(HO1) in the bioreactor cultures growing in modified
ZY medium in fed-batch mode with lactose and glycerol. In contrast, the two strains
produced approximately the same amounts of biliverdin when grown in LB medium with
lactose (2.5% wt·vol-1) in small shaker flasks (Table 2-1). When peptone was included in
the fed-batch medium (together with lactose and glycerol), E. coli strain BL21(mHO1)
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bioreactor cultures produced between18.4 to 25.3 mg·L-1 (n=11, average of 23.8 mg·L-1)
of biliverdin. E.coli strain BL21(HO1) produced between 3 and 3.9 mg·L-1 (n=9, average
of 3.3 mg·L-1) in modified NBS medium in batch mode.
Biliverdin production was also achieved in 100 L bioreactor (Braun UE-100D)
batch mode cultures of E. coli strain BL21(HO1) grown in NBS medium containing 2%
(wt·vol-1) lactose. Biliverdin yields ranging between 200 to 311 mg (n=5, average 212)
were achieved. This rate of production was similar to that achieved by E. coli strain
BL21(HO1) in the 2 L bioreactor (BioFlo® 310) batch mode cultures (average rate: 3.3
mg·L-1) indicating that biliverdin production by E. coli strain BL21(HO1) is scalable to
larger volumes and quantities.
HO expression and activity
When grown in 2 L bioreactor cultures, E. coli strain BL21(mHO1) cells
contained Ni-NTA recoverable proteins with molecular size ~29 kDa and detectable
initially between 2 to 5 h after inoculation and then until growth was terminated (25 h)
(Figure 2-4). The proteins were equivalent in size to ho1 of Synechocystis PCC6803 with
a 6× His tag (i.e. 28.7 kDa) and the gel excised protein showed sequence similarity to the
cyanobacterial ho1 (31% sequence coverage, Mascot protein score =146). Extracts of E.
coli strain BL21(mHO1) cells harvested at 25 h of bioreactor growth had HO activities of
80 pmol·hr-1·mg protein-1 whereas extracts from E. coli strain BL21 Star™ (DE3) cells
showed no or barely detectable activities (<5 pmol·hr-1·mg protein-1). These results
confirmed that E. coli strain BL21(mHO1) synthesized an HO enzyme when grown
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under conditions that allowed accumulation of green pigment determined to be biliverdin
(see below).
Identification of biliverdin IXα
The identity of the biliverdin extracted from E. coli strain BL21(mHO1) cultures
as biliverdin IXα was indicated by comparisons to authentic biliverdin IXα using
absorbance spectroscopy, HPLC, proton NMR spectroscopy (Figure 2-5) and mass
spectroscopy (mass 582.2). The degree of purity was >98% based on HPLC profiles
(biliverdin IXα retention time of 6.6 min, Figure 2-5.B).
E. coli produced biliverdin as substrate
for biliverdin reductase A
Purified biliverdin produced by E. coli BL21(mHO1) was reduced to bilirubin
IXα by recombinant human biliverdin reductase A and NADPH (Figure 2-6). Since
human biliverdin reductase A specifically uses biliverdin IXα as substrate [1, 35] this
result confirms the identity of the E. coli BL21(mHO1) produced biliverdin as the IXα
isomer. It also suggests that the produced biliverdin has therapeutic potential because of
its substrate interaction with the human enzyme and its facile conversion to bilirubin IXα.
Conclusions
Methods for the scalable production of biliverdin by E. coli cultures were
developed. Production is enhanced with the use of an altered version of a cyanobacterial
ho1 gene that is sequence-optimized for E. coli expression. The produced biliverdin is
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solely the physiologically relevant IXα isomer and is easily obtained at a high degree of
purity (>98%). Its purity and ability to serve as substrate for human NADPH biliverdin
reductase A suggest its potential as a clinically useful therapeutic for inflammatory
diseases and conditions. When commercially produced for therapeutic applications, the
biliverdin IXα preparations will undoubtedly require screening for and elimination of
endotoxin contaminants that are a consequence and limitation of industrial scale
production by E. coli cultures.
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Table 2-1 Biliverdin production by E. coli strain BL21(HO1) and BL21(mHO1)
with growth in LB medium supplemented with various sources
E. coli strain
BL21(HO1)

Carbon Source
D-glucose
sucrose
D-mannitol
D-sorbitol
lactose

D-mannitol/D-glucose
sucrose/D-glucose
D-mannitol/D-sorbitol
lactose/D-glucose
succinate
malate
citrate
L-glutamate
L-glutamate
BL21(mHO1) D-glucose
D-mannitol
lactose
lactose/D-glucose
aIsopropyl-β-thiogalactoside

Conc. %
1
2
5
1
1
2
5
1
5
10
1
2.5
5
10
1.1/1.1
1.1/1.1
2.5/2.5
2/5
5/5
2/2
5
5
5
5
5

IPTGa
+
+
+
+
+
+
+
+
+
+
‒
‒
‒
‒
+
+
+
+
+
‒
+
+
+
+
+

Pigmentb
pale green
pale green
yellow green
brown
pale green
pale green
green
yellow green
yellow green
yellow green
pale green
green
yellow green
yellow green
pale green
pale green
green
green
green
green
pale green
pale green
pale green
pale green
yellow green

1
5
2.5
2/2

+
+
‒
‒

Green
Green
Green
Green

(IPTG), 0.5 mM added (+), or not added (−).
Biliverdin concentrations were 2 to 4 mg·L-1 (green), <2 to >0.2 mg·L-1 (pale green)
and <0.2 mg·L-1 (yellow green and brown).
b
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Figure 2-1 Gene maps of expression vectors pET101 HO1 (A) and pJexpress401-mHO1
(B). ho1 gene expression in (A) is controlled by T7 lac promoter which consists of a
strong bacteriophage T7 promoter and a downstream 25 bp lac operator in pET101. For
mho1 expression (B), an “IP-free” T5 promoter sequence was used with the lac operator
placed downstream of the T5 promoter in the vector pJexpress 401.
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Figure 2-2 Gene sequence of ho1 of cyanobacterium Synechocystis PCC6803 (red), E.
coli expression optimized mho1 gene sequence (blue) and the corresponding ho1 protein
sequence (black).
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Figure 2-3 Biliverdin production from E. coli strain BL21(mHO1) growing in modified
ZY medium in a New Brunswick BioFlo ® 310 bioreactor. Biliverdin is subsequently
extracted from the green-colored material that accumulates above the culture surface.
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Figure 2-4 SDS-PAGE of eluted solutions from Ni-NTA columns of cell extracts derived
from bioreactor cultures of E. coli strain BL21(mHO1) harvested at various times during
growth on ZY medium. Gel lanes are: mixture of protein molecular size standards (a),
and cell extracts from cultures harvested at 2 h (b), 5 h (c), 10 h (d), 15 h (e) and 25 h (f)
after culture inoculation. Expression of MW ~29 kDa ho1 is evident (right arrow) and not
visible when derived from cells grown without lactose or with glucose (+IPTG) (not
shown). Gel positions of 37 kDa and 25 kDa protein markers are indicated by arrows
(left side).
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Figure 2-5 Spectral and chromatographic analyses of biliverdin produced by bioreactor
cultures of E. coli BL21(mHO1). (A) Absorbance spectra of biliverdin produced by E.
coli BL21(mHO1) (red) and commercial biliverdin IXα derived from an animal source
(blue). (B) HPLC chromatograms of biliverdin produced by E. coli BL21(mHO1) (top)
and commercial biliverdin IXα derived from an animal source (bottom). (C) One
dimensional proton NMR (400 Mhz) spectrum of E. coli BL21(mHO1)-produced
biliverdin in DMSO-d6. 1H NMR (400 MHz, DMSO) signal assignments are: 12.32 (s;
2H); 12.1(s; 1H); 12.01 (s; 1H); 10.78 (s; 1H); 10.67 (s; 1H); 7.58 (s; 1H); 6.91 (t, J=
15.6 Hz; 1H); 6.69 (t, J= 15.2 Hz; 1H); 6.32 (d, J= 12.2 Hz; 3H); 5.82 (d, J=10.8 Hz; 1H);
5.56 (d, J= 11.2 Hz; 1H); 5.78 (s; 1H); 3.05 (m; 4H); 3.43 (m; 4H); 2.18 (s; 3H); 2.27 (s;
3H); 2.15 (s; 3H); 2.01 (s; 3H) and similar to those reported for biliverdin IXα derived
from animal sources [36].
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Figure 2-6 Absorbance spectra at various times during bilirubin formation from E. coli
BL21(mHO1) produced biliverdin catalyzed by human recombinant biliverdin reductase.
NADPH-dependent reduction was monitored spectrophotometrically for 6 h. The arrows
indicate the direction of absorbance changes over time during the reaction.
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CHAPTER 3
ENHANCED BILIVERDIN IXα PRODUCTION BY RECOMBINANT
ESCHERICHIA COLI WITH OVEREXPRESSION OF ELECTRON
DONORS FOR TRANSFORMED HEME OXYGENASE
Introduction
Heme oxygenase (HO, EC:1.14.99.3) is an oxygen-dependent enzyme which
cleaves the tetrapyrrole ring of heme at the α-methene bridge and forms equimolar
amounts of linear tetrapyrrole biliverdin IXα, Fe2+, and carbon monoxide. There are two
HO isozymes, stress-inducible HO1 concentrated in tissues (e.g., spleen and liver) and
constitutive HO2 concentrated in neural tissues (10, 12, 63). Though HO is widely
distributed in animals, insects, higher plants, cyanobacteria, algae, fungi, and some
pathogenic bacteria, the product biliverdin IXα is found as a final product only in lower
vertebrates. In cyanobacteria, biliverdin IXα is produced as a substrate in bilin
chromophore synthesis for light-harvesting (3, 8). In mammals, HO1 is important in
degradation of pro-oxidant heme from a series of hemeproteins, including hemoglobin
from aged red blood cells (42, 57). Hemoglobin heme is mainly degraded by HO1, and
the product biliverdin IXα is subsequently converted into bilirubin IXα by biliverdin
reductase (EC: 1.3.1.24) of phagocytic cells in the spleen and liver (41). Bilirubin IXα is
highly hydrophobic and binds to albumin for circulation and transportation to the liver,
where the bilirubin IXα-albumin bond is broken and a glucuronic acid conjugate of
biliverdin IXα is formed for excretion from the body in bile and feces (15, 28). Though

56
bilirubin IXα was once considered as a toxic waste product (18, 19, 45, 48), its property
as a potent anti-oxidant at lower concentrations has been recognized to be of
physiological importance (2, 31, 39, 49, 56, 58, 62). The bilirubin IXα-albumin complex
can be oxidized by peroxyl radicals, which cause lipid peroxidation, to a biliverdin IXαalbumin complex in plasma and the extravascular space (33, 47, 49). One mol of
bilirubin IXα-albumin can scavenge two moles of peroxyl radicals. Cell protection from
10,000-fold excess of peroxyl radicals has been reported with the biliverdin reductase
amplified biliverdin IXα/bilirubin IXα redox cycle in vitro (2). Also, biliverdin reductase
mediates serine/threonine/tyrosine kinase activity when it is bound with biliverdin IXα,
and then initiates cell signaling pathways leading to anti-inflammatory responses and
suppression of cellular pro-inflammatory events (29, 61). Administration of biliverdin
IXα, a less toxic but more hydrophilic form than bilirubin IXα, has been reported to be
effective against ischemia and reperfusion injuries (1, 14, 38), diabetes (22, 55), lung
injuries (26, 44), HIV (37), and hepatitis (65).
The enzymatic activity of HO1 is the rate-limiting step in the degradation of
senescent hemeproteins into biliverdin IXα which consumes seven electrons and strongly
depends on the presence of electron donors (25, 30, 64). Both mammalian and
cyanobacterial HO1 use NADPH as the electron source, though they have different
mediator molecules for electron transportation. Mammalian HO1 has a hydrophobic tail
on its C-terminus and is anchored to the microsomal membranes (46, 52). This
localization allows electron transfer through NADPH-cytochrome P450 reductase (CPR).
CPR consists of four structural domains, the flavin mononucleotide (FMN)-binding
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domain, the connecting domain, the flavin adenine dinucleotide (FAD)-binding domain,
and the NADPH-binding domain, connected in sequence from the N- to C- temini (60).
The FMN-binding domain is similar to the structure of Fld, whereas the FAD-binding
domain and NADPH-binding domain are similar to those of ferredoxin-NADP + reductase
(FNR).

Electrons from NADPH flow first to the FAD prosthetic group of CPR and then

to FMN prosthetic group of CPR and finally to HO1 for heme degradation (5, 7). A
similar directional electron flow is also observed in cyanobacteria. Cyanobacterial HO1
does not have an anchor tail on its C-terminus while amino acid residues around the heme
binding site are highly conserved (e.g., 57% similarities between human HO1 and
Synechocystis PCC 6803 HO1) (51). Though catalytic activity of cyanobacterial HO1
was reported with CPR as the electron donor, its narrower heme-/electron donor-binding
site prefers plant-type 2Fe-2S ferredoxin (Fd, ~10 kDa) rather than CPR (~77 kDa) (51).
In cyanobacteria, electrons flow from NADPH to FNR which contains FAD as the
prosthetic group, FNR to Fd, and then Fd to HO1 (9, 27).
Flavodoxin (Fld) is a small soluble flavoprotein (14-23 kDa) which has a noncovalently bound FMN molecule as a prosthetic group instead of an iron-sulfur cluster
(13). It is isofunctional to ferredoxin and able to mediate NADP + reduction via FNR
(32). While Fd is distributed throughout all kingdoms from prokaryotes to animals, Fld is
only found in prokaryotes and some eukaryotic algae (66). In general, Fd is used as a
major electron carrier while Fld is induced under adverse conditions. For instance,
cyanobacteria produce Fld under iron-deficient conditions to replace Fd in spite of their
different structures, sizes, and redox cofactors (5, 17). Few organisms like Escherichia
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coli and Helicobacter pylori are known to require Fld as a specific electron carrier for
their survival (16, 21, 40).
In our previous study, cyanobacterial HO1 was expressed in E. coli BL21(DE3)
and the new E. coli construct was grown in fermenters for scalable production of
biliverdin IXα (6). Although some pathogenic strains of E. coli (e.g., O157:H7) have
HO for iron acquisition, biliverdin IXα production in wild-type strains has not been
reported (53, 54). Lack of native redox partners for the heterologous HO1 may limit
biliverdin IXα production in the current recombinant of E. coli strain. The aim of this
study was to obtain a strain with improved biliverdin IXα production by overexpression
of the proteins, Fld or FNR.
Materials and Methods
E. coli strain
E. coli BL21(mHO1-GFP) was used as the host for overexpression of electron
donors for enzymatic activity of transformed HO1 (6). Briefly, the ho1 gene from
Synechocystis sp. PCC6803 was sequence-optimized for expression (mho1) in E. coli and
incorporated with green fluorescent protein at the 5’-terminus. The mho1-gfp gene was
synthesized and inserted into plasmid vector pJexpress401 (DNA2.0 Inc., Menlo Park,
CA). The resulting vector pJexpress401-mho1-gfp was transformed into One Shot®
BL21 StarTM (DE3) Chemically Competent E. coli (Life Technologies, Carlsbad, CA) to
give E. coli strain BL21(mHO1). The resulting strain was grown in LB amended with
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100 µg·mL-1 kanamycin as the selectable marker. Calcium competent E. coli
BL21(mHO1-GFP) was prepared and stored at ‒70℃ (43).
Plasmids for overexpressions of electron
donors
The plasmid pET11a-fpr (23, 24) (Fig. 3-1. A), pET11 vector with the fpr gene
encoding FNR from E. coli strain JM109, was obtained as a gift from Dr. M. Waterman
(Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN)
and the plasmid pDH122M (4) (Fig. 3-1. B), pTRC99A vector with the fldA gene
encoding Fld, was kindly provided by Dr. M. Koutmos (Uniformed Service University of
the Health Science, Bethesda, MD). Both plasmids have ampicillin as the selectable
marker. Strain BL21(mHO1-GFP+FNR) and BL21(mHO1-GFP+Fld) were obtained by
transformations of pET101-fpr and pDH122M into chemically competent cells of E. coli
BL21(mHO1-GFP), respectively.
Biliverdin IXα production in shake flasks
For production of biliverdin IXα in baffled flasks with shaking, E. coli strain
BL21(mHO1-GFP), BL21(mHO1-GFP+FNR), and BL21(mHO1-GFP+Fld) inocula were
grown in test tubes containing 5 mL of LB broth amended with 100 µg·mL -1 of
kanamycin or kanamycin and ampicillin with rotary shaking (200 rpm) at 30℃ overnight.
Inoculum cultures were added into 100 mL New Brunswick Scientific (NBS) medium
(59) supplemented with 2% lactose and 100 µg·mL-1 corresponding selectable markers
(kanamycin or kanamycin and ampicillin) in 250 mL capacity baffled flasks for biliverdin
IXα production. Flasks were incubated at 37℃ with rotary shaking (200 rpm) for 2 days
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until the green product appeared as rings above cultures on the inner wall of flasks.
Absorbance at 600 nm was measured at the end of growth. The production in flasks was
repeated three times for each strain.
Biliverdin IXα production in a fed-batch
fermenter system
Fermentative production of biliverdin IXα was performed with strain
BL21(mHO1-GFP) and BL(mHO1-GFP+Fld) to show their scalability in fermenters.
Inocula were prepared in 250 mL capacity baffled flasks containing 50 mL of Yeast-Hy
ES II medium, 5 g·L-1 Hy-Yeast® 444 (Sigma-Aldrich, St. Louis, MO) and 15 g·L-1 HyExpressTM System II (SheffieldTM Bio-Science, Norwich, NY) mixed with 16 g·L-1
glycerol, 25 g·L-1 glucose, 1.5 mL·L-1 trace element solution I (0.25 g CuSO4·5H2O, 2.4
g MnSO4·H2O, 0.30 g Na2MoO4·2H2O, 2.5 g Ni(NO3)2, 1.5 g ZnSO4, and 0.3 mL 6 N
H2SO4 in distilled water to make a final volume of 100 mL), 1.5 mL·L-1 trace element
solution II (0.5 g NaCl, 0.475 g FeCl3·6H2O, 0.075 g CoCl2·6H2O, 0.05 g H3BO3, 0.29 g
CaCl2·2H2O, 0.3 mL 6 N H2SO4 in distilled water to make a final volume of 100 mL) 50
mL·L-1 20× NP stock solution (66 g (NH4)2SO4, 136 g KH2PO4 and 142 g Na2HPO4 in
distilled water to make a final volume of 1 L), 0.5 g·mL-1 MgSO4, 0.4 mg·L-1 thiamine,
and 100 µg·mL-1 of kanamycin or kanamycin and ampicillin after autoclaving. The
inoculum cultures were grown at 30℃ with rotary shaking (200 rpm) for 12 h. Biliverdin
IXα production was conducted in a New Brunswick BioFlo ® 310 Benchtop Fermentor &
Bioreactor System (New Brunswick Scientific Co., Endfield, CT) with BioCommand ®
Software (Eppendorf, Inc., Hauppauge, NY) and a 5-L capacity vessel filled with 3.5 L
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modified ZY medium (6, 50), 2 g·L-1 lactose, 2.2 g·L-1 glucose, 16 g·L-1 glycerol, 10
g·L-1 Hy-ExpressTM System II, 5 g·L-1 Hy-Yeast® 444, and 2 mM MgSO4 mixed with 50
mL 20× NP stock solution and 1 mL·L-1 of trace element solution III (0.2% HCl, 0.27 g
FeCl3, 0.08 g CaCl2·2H2O, 0.063 g MnCl2·4H2O, 0.011 g ZnSO4·7H2O, 0.01 g NiCl2,
0.012 g Na2MoO4·2H2O, and 0.003 g H3BO3 in 100 mL distilled water) after autoclaving.
A dissolved oxygen level was maintained at 40.0% by program-controlled agitation (300600 rpm) and aeration (1.0-3.0 slpm, 0-100% O 2 in air), and temperature was kept at
37℃. Feeding of 100 g·L-1 glycerol, 50 g·L-1 Hy-ExpressTM System II, and 20 g·L-1
lactose was initiated 4 h after inoculation at 25 mL·h -1. Green pigment accumulated in
the foam above the bioreactor culture was collected by siphoning. The fermentation run
was repeated three times for each strain.
HPLC quantification of biliverdin IXα
Product biliverdin IXα in growth medium was extracted with 0.1 M ammonium
acetate in 20% methanol. After removal of cell debris by centrifugation at 10,000×g for
10 min, 1 mL of the supernatant was loaded on a 1mL capacity C18 Resprep ® SPE
Cartridge (Restek, Bellefonte, PA) pre-equilibrated by sequential elution with 1 mL
methanol and 1 mL 0.1 M ammonium acetate. The cartridge was washed with 1 mL 0.1
M ammonium acetate, and biliverdin IXα was eluted with 1mL 30% 0.1 M ammonium
acetate/70% methanol (vol·vol-1) solution. The prepared sample was loaded to a
Beckman System Gold RP-HPLC instrument (Beckman Coulter, Inc., Brea, CA) on a
150×4.6 mm Beckman Ultrasphere C18 column (Beckman Coulter, Inc., Brea, CA). The
elution gradient of solvent A: 0.1% (v·v-1) TFA in distilled water and solvent B: 0.1%
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(v·v-1) TFA in methanol was 0% solvent B, 1 min; 0-60% solvent B, 1 min; 60-100%
solvent B, 8 min; 100% solvent B, 3 min with a flow rate of 1.0 mL·min -1. The elution
was monitored at 385 nm and fractions were collected separately every 1 min. The
biliverdin IXα peak was identified and quantified based on comparisons with known
amounts of commercial biliverdin IXα (Frontier Scientific, Inc., Logan, UT).
Protein extraction
Cultures of E. coli strain BL21(mHO1-GFP) and BL21(mHO1-GFP+Fld) were
grown in 250 mL capacity baffled flasks containing 50 mL of NBS medium
supplemented with 2% lactose and 100 µg·mL-1 kanamycin or kanamycin and ampicillin.
After 24 h incubation with shaking at 30℃, cells were harvested by centrifugation at
4,000×g for 20 min. Soluble proteins were extracted by acetone-precipitation and buffersolubilization (11). Briefly, cells collected from 20 mL of 24 h old culture were
sonicated in 4 mL homogenization buffer (50 mM Tris-acetate pH 8.0, 10 µM
phenylmethylsulfonyl fluoride, 1 mM EDTA, and 1 mM β-mercaptoethanol) on ice for
30 s. Homogenized samples were combined with 36 mL acetone and agitated for 1 h at
0℃. Insoluble materials in 90% (v·v-1) acetone were collected by centrifugation at
15,000×g for 15 min and dried under a stream of air. Proteins were re-suspended in 2 mL
sample buffer (50 mM Tris-acetate pH 8.0, 10 µM phenylmethylsulfonyl fluoride, and 1
mM EDTA) and agitated at 200 rpm and 0℃ for 24 h. Then cell debris was removed by
centrifugation at 10,000×g and 4℃ for 20 min. The concentrations of crude soluble
proteins were estimated by measurements of absorbance at 280 nm (A 280).
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SDS-PAGE
Soluble protein extracts of E. coli strain BL21(mHO1-GFP) and BL21(mHO1GFP+Fld) were subjected to SDS-PAGE (15% acrylamide gel). Wells were loaded with
2.5 or 12.5 µL of soluble protein extracts mixed with 2.5 or 12.5 µL 2× SDS-PAGE
loading buffer and 3 µL BLUEstainTM Protein ladder (Gold Biotechnology, Inc., St.
Louis, Mo). The gel was electrophoresed with Tris-glycine buffer using an ISCO Model
470 Power Supply (ISCO Inc., Lincoln, NE).
Results
Biliverdin IXα production in shake flasks
Biliverdin IXα product accumulated on the inner walls of baffled flasks was
harvested with methanol at 48 h. Based on HPLC quantification of the methanol wash,
the yields were 2.00±0.03 mg·L-1, 1.20±0.15 mg·L-1, 2.45±0.13 mg·L-1 by strains
BL21(mHO1-GFP), BL21(mHO1-GFP+FNR), and BL21(mHO1-GFP+Fld), respectively
(Table 3-1. A). The strain BL21(mHO1-GFP+FNR) had 40.1±7.6% lower yield while
strain BL21(mHO1-GFP+Fld) had 17.8±5.5% higher yield comparing to strain
BL21(mHO1-GFP).
Biliverdin IXα production in a fed-batch
fermenter system
Production of biliverdin IXα by E. coli strain BL21(mHO1-GFP) and
BL21(mHO1-GFP+Fld) was conducted in a BioFlo® 310 Benchtop Fermentor &
Bioreactor System. Both cultures of both strains had a common pattern of pH changes
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during growth (Fig. 3-3). When E. coli was grown without feeding, the pH changed in a
similar way at 0-7.5 h but kept decreasing after 7.5 h (data not shown). Feeding was
started once the pH started to re-increase at 4 h, and initiation of green pigment
production was observed at 7.5 h when the pH hit the bottom value of ~5.2. At 20 h, the
estimated biliverdin IXα yields based on HPLC were 9.09±2.49 mg·L-1, and 13.17±1.71
mg·L-1 by BL21(mHO1-GFP) and BL21(mHO1-GFP+Fld), respectively (Table 3-1. A).
Protein extraction and SDS-PAGE
Soluble proteins were extracted from 24 h old cultures by acetone-precipitation
and solubilized in buffer. The concentrations were estimated as 401.3±25.2 µg·mL-1 for
strain BL21(mHO1-GFP) and 419.3±7.0 µg·mL-1 for strain BL21(mHO1-GFP+Fld)
based on measurements of A280 (n=3). Separation of soluble proteins was performed by
SDS-PAGE in Tris-glycine buffer. The extract of strain BL21(mHO1-GFP+Fld) had a
visible band at 20 kDa, while the extract of strain BL21(mHO1-GFP) had a diffused tail
of 21 kDa band at this size (Fig. 3-2). The protein extract from E. coli strain
BL21(mHO1-GFP+Fld) had overexpression of a ~20 kDa protein which is predicted as
Fld (36).
Discussion
Plasmids pET11a-fpr and pDH122M were transformed into E. coli BL21(mHO1GFP) for the purpose of providing potential electron donors, FNR and Fld, for enzymatic
activity of heterogeneous mHO1. In baffled flasks, a 17.8±5.5% higher biliverdin IXα
yield was achieved with overexpression of Fld with pDH122M while overexpression of
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FNR with pET11a-fpr lowered biliverdin IXα yield by 40.1±7.6%. Also, the cell density
measurements (A600) of E. coli strain BL21(mHO1-GFP+Fld) was 13.0±5.9% higher than
the measurements of strain BL21(mHO1-GFP) (Table 3-1. B). The biliverdin IXα
production by BL21(mHO1-GFP+Fld) was scalable in a New Brunswick BioFlo ® 310
Benchtop Fermentor & Bioreactor System. The fed-batch fermentation of strain
BL21(mHO1-GFP+Fld) achieved 40.8±9.1% higher yield of biliverdin IXα and
26.1±2.0% higher A600 comparing to strain BL21(mHO1-GFP).
The fldA gene belongs to the soxRS (superoxide response) oxidative stress regulon
of E. coli and lack of the fldA gene can be lethal under both aerobic and anaerobic
conditions (16). Overexpression of cyanobacterial Fld in E. coli was reported to confer
resistances against oxidative stress inducers such as paraquat and atrazine (7). In this
study, E. coli was grown to achieve high cell densities, and higher A 600 was achieved in
the culture of E. coli strain BL21(mHO1-GFP+Fld) than the culture of strain
BL21(mHO1-GFP). Though the aim to overexpress fldA was to increase electron
transfer to mHO1, Fld possibly functioned as a cell protectant under highly stressed
condition or by preventing protein denaturation of mHO1. Further study will be required
to clarify the role of Fld flavoprotein in biliverdin IXα production.
The new E. coli construct described in this work revealed a 17-40% increase in
biliverdin IXα production with overexpression of the fldA gene that encodes Fld. The
biliverdin IXα production was shown to be scalable in a fermenter. Current
commercially available biliverdin IXα is prepared by chemical oxidation of bilirubin IXα
extracted from animal bile (34), a process that generates significant levels of

66
contaminants like biliverdin IIIα and XIIIα isomers (35). This chemical conversion
requires further chromatographic procedures to obtain the biologically active biliverdin
IXα isomer in pure form (20). On the other hand, enzymatic cleavage of heme by HO1 is
a site-specific reaction and transformed E. coli solely produces the IXα isomer as
reported in our previous study (6). Fermentative production of biliverdin IXα
accumulates the product in the foam above the culture and greatly facilitates its
purification. Biliverdin IXα biosynthesis by E. coli offers the potential for scalable
production and high degrees of purity of this compound for medical applications.
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TABLE 3-1. Biliverdin IXα yields and final A600 in baffled flasks and fermenters
A. Biliverdin IXα yields estimated by HPLC quantifications
E. coli strain
BL21(mHO1-GFP)
BL21(mHO1GFP+FNR)
BL21(mHO1GFP+Fld)

Biliverdin IXα yield (mg·L-1)

1

st

2.00

flask (48 h)
2nd

3

rd

fermenter (20 h)
1
2nd
3rd
st

1.96

2.05

5.89

7.40

13.99

1.50

1.00

1.10

-

-

-

2.56

2.60

2.20

12.62

13.71

18.20

B. Cell density measurements as A600
E. coli strains
BL21(mHO1-GFP)
BL21(mHO1GFP+FNR)
BL21(mHO1GFP+Fld)

1

st

4.56

flask (48 h)
2nd

final A600
3

rd

fermenter (20 h)
1
2nd
3rd
st

5.28

4.70

45.4

47.1

46.9

4.48

4.88

5.12

-

-

-

5.68

5.54

5.15

56.1

58.7

61.0

A

B

FIG. 3-1. Gene maps of expression vector pET11a-fpr (A) and pDH122M (B)
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FIG. 3-2. SDS-PAGE of soluble protein extracts. Gel lanes are protein standards (A), E.
coli BL21(mHO1-GFP) extract (B=2.5 μL and C=12.5 μL), and BL21(mHO1-GFP+Fld)
extract (D=2.5 μL and E=12.5 μL). The white arrows indicate ~21 kDa band and the
black arrow indicates ~20 kDa band. The ~20 kDa band was observed with
BL21(mHO1-GFP+Fld) extract.
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FIG. 3-3. Growth curves (A600) and pH changes in a bioreactor. The A600 and pH
measurements are shown as solid and dotted lines, respectively. A is from the growth of
E. coli strain BL21(mHO1-GFP) (3rd experiment) and B is from the growth of strain
BL21(mHO1-GFP+Fld) (3rd experiment).

77
CHAPTER 4
*PRODUCTION AND APPLICATION OF SYRINGOMYCIN E AS AN ORGANIC
FUNGICIDE SEED PROTECTANT AGAINST PYTHIUM DAMPING-OFF
Abstract
Syringomycin E (SRE) is a cyclic lipodepsinonapeptide with potent antifungal
activity produced by certain strains of Pseudomonas syringae pv. syringae. In this study,
its potential as an organic-compatible agrofungicide and seed treatment against the soilborne pathogen Pythium ultimum var. ultimum was examined. A variant of P. syringae
pv. syringae strain B301D with enhanced SRE-producing capabilities was isolated and
grown in a bioreactor with SRE yields averaging 50 mg·L-1 in 40 h. SRE was extracted
and purified through a large-scale chromatography system using organic-compatible
processes and reagents. The minimum concentrations of the purified product required to
inhibit 50 and 90% of P. ultimum oospore germination were determined as 31.3 and 250
µg·mL-1, respectively. Drench treatment of cucumber seeds in P. ultimum infested
potting medium (500 oospores·g-1) with 50 µg·mL-1 SRE resulted 90.2±4.5% sprouting
while control water drench had 65.7±4.6% sprouting. Seed coating with 0.03% (w·w -1)
SRE allowed 65.7±4.6% seedlings to emerge on naturally ingested soil while
100.0±0.0% of non-coated seeds were depleted by Pythium infection. Organiccompatible SRE has potential as a novel organic fungicide seed protectant.
* Yukie Kawasaki, Claudia Nischwitz, Michelle Grilley, Justin Jones, Jason Brown, and
Jon Y. Takemoto
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Introduction
Strains of Pseudomonas syringae pv. syringae are either epiphytes or
opportunistic pathogens on healthy or diseased plants. They produce two classes of nonribosomal cyclic lipodepsipeptides commonly known as syringomycins and
syringopeptins (Hutchison and Gross 1997; Little, Bostock, and Kirkpatrick 1998).
Syringomycins are relatively small molecules (MW 1100-1300 Da) with potent
antifungal activities, while syringopeptins are larger (MW 2200-2500 Da) and have both
antimicrobial and phytotoxic activities (Fukuchi et al. 1992; Grgurina et al. 2005;
Iacobellis et al. 1992; Raaijmakers et al. 2006; Takemoto 1992). Syringomycin E (SRE)
is a predominant syringomycin analog and consists of a 3-hydroxydodecanoic acid and a
nine amino acid peptide ring (Segre et al. 1989). This amphipathic structure interacts
with the plasma membranes of fungi and forms lipidic ion channels (Feigin et al. 1996;
Hama et al. 2000; Kaulin et al. 1998, 2005; Malev et al. 2002, 2008). SRE channels are
voltage-dependent and slightly selective for anions. The resultant fluxes of H +, K+, and
Ca2+ ions result in ionic imbalances that are lethal to the target cells (Hutchison et al.
1995; Schagina et al. 2003; Takemoto et al. 1989). Antifungal activities of SRE have
been reported against many fungal species, including soil-borne pathogens such as
Pythium, Fusarium, and Rhizoctonia (De Lucca et al. 1999).
Soil-borne fungal and oomycete phytopathogens are major causes of crop loss in
the USA and are difficult to control (Bonanomi et al. 2007). P. ultimum is a widespread
oomycete which mainly survives as oospores in temperate regions (Hendrix and
Campbell 1973). Its oospores are resistant to desiccation and other extreme
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environmental conditions, and they survive in soil for several years in the absence of
suitable hosts (Martin and Loper 1999). The germinated oospores quickly grow and
colonize host plants by producing hyphae. Oospore germination triggers damping-off
disease of sprouting seeds (Al-Sheikh and Abdelzaher 2010; Hancock 1981). Natural
plant resistance against damping-off disease is weak, and as a consequence P. ultimum
infection has been a common problem in many fields and greenhouses (Benhamou and
Bélanger 1998; Georgakopoulos et al. 2002). Soil drench and seed treatment with
chemical fungicides are common approaches to prevent infections by Pythium and other
soil-borne pathogens (Koch 1999; Taylor and Harman 1990). Phenylamides (e.g.,
metalaxyl, mefenoxan) and captan have been used to control Pythium infections (Casas et
al. 1990; Hwang et al. 2001; Raaijmakers et al. 2009). However, for organic farming in
the USA, these conventional synthetic fungicides are not allowed and losses of crops due
to oomycetes and fungi are serious problems for this agricultural sector.
As a secondary metabolite natural product SRE is a potential natural fungicide for
disease control applications (Takemoto et al. 2010). Its inhibitory activities against
oosporic phytopathogens such as Pythium sp. make it particularly attractive to explore as
a seed protectant against diseases caused by these pathogens. However, current SRE
production and purification methods are not suitable for large scale production and
organic farming applications. In the past, P. syringae pv. syringae B301D was
principally used for the production of SRE in potato dextrose broth (PDB) medium
(Gross and DeVay 1977a; Zhang and Takemoto 1987), syringomycin minimal (SRM)
broth (Gross 1985; Mo and Gross 1991) or improved minimal medium (IMM) broth
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(Surico et al. 1989), and provided SRE levels in milligram quantities after several days of
growth, typically without agitation. The extraction and purification methods typically
involved reagents (e.g. butanol, acetone, and methanol) that are not allowed by the
USDA for products used for organic applications (USDA 2015). The goals of this study
were to: 1) produce scalable amounts of SRE by methods that allow qualification for
organic use certification (e.g. USDA), and 2) determine the capabilities of the produced
SRE to serve as an effective seed protectant agrofungicide against Pythium infections.
Materials and Methods
Isolation of enhanced SRE-producing
strain P. syringae pv. syringae strain G10
Logarithmically growing cultures of P. syringae pv. syringae strain B301D were
spread onto potato dextrose agar plates at a concentration of 5×10 3 cells per plate. Plates
were inverted without lids onto an ultraviolet light source (Transilluminator, UVP,

Upland, CA), irradiated at 302 nm for 10 s, and then placed in the dark at 28℃ for 2

days. Surviving colonies (survival rate was approximately 10%) were inoculated in 0.1
mL PDB supplemented with 0.4% (w·v-1) casamino acids (PDBCA) in 96-well microtiter
plates, 28℃. After growth, 0.05 mL of each culture was removed, extracted with an
equal volume acetone acidified with 0.4% (v·v-1) HCl, dried, and then suspended in 0.05
mL sterile water. Extracts were tested for antifungal activity by placing 0.02 mL of the
suspended material onto a lawn of Rhodotorula pilimanae (Zhang and Takemoto 1987).
The isolates with extracts showing the largest zones of growth inhibition were subjected
to a second round of UV mutagenesis and selection, yielding P. syringae pv. syringae

81
strain 2B6. Strain 2B6 underwent a third round of mutagenesis, as above, except ISM
medium (see below) was used in place of PDB CA in the 96 well microtiter plate. Isolates
showing greatest antifungal activity at this stage were subcultured by the addition of 0.02
mL of culture to 3 mL ISM in a test tube. Antifungal activity was tested again after 48 h
incubation at 28℃ on a rotary shaker and SRE levels quantified by HPLC. The strain
which produced the greatest amount of SRE under these conditions was named P.
syringae pv. syringae strain G10.
Medium modification
Modifications of growth medium, SRM (1% glucose, 0.4% histidine, 0.8 mM
MgSO4, 1 mM FeCl3, and 0.8 mM potassium phosphate, pH7) (Gross 1985; Mo and
Gross 1991) were performed to improve SRE production by P. syringae pv. syringae
strains. The antifungal activities of P. syringae pv. syringae strain 2B6 culture extracts
(estimated by visual inspection of R. pilimanae growth inhibition zones on potato
dextrose agar) were examined as a function of different carbon compounds substituted for
1% (w·v-1) glucose in SRM. Tested were glycerol, ribose, galactose, mannitol, lactic
acid, acetate, or succinate, each at 1% (w·v-1), glucose plus mannitol, each at 1 or 2%
(w·v-1), glucose, 1% (w·v-1), plus fructose, 0.1% (w·v-1), and arbutin, 100 µM, and
glucose, 1% (w·v-1), plus fructose, 0.1% (w·v-1), and salicylate, 100 µM. The inclusion
of 1% (w·v-1) glucose plus 1% (w·v-1) mannitol gave the highest antifungal activity, and
this mannitol-supplemented SRM was named “improved SRE medium” or “ISM.” SRE
production by P. syringae pv. syringae strain G10 was examined with growth in SRM,
ISM, SRM plus 100 µM arbutin and 0.1% (w·v-1) fructose, ISM plus 100 µM arbutin and
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0.1% (w·v-1) fructose, and SRM plus 100 µM salicylate and 0.1% (w·v -1) fructose in
agitated flask cultures.
Scalable SRE production
P. syringae pv. syringae strain G10 was initially grown in 500 mL of ISM with
rotary shaking (200 rpm) at 28℃ for 15 h. The 500 mL culture was used as inoculum for
a 10 L ISM culture in a 10 L-working volume Winpact Bioreactor and Fermenter System
(Major Science, Saratoga, CA) with conditions maintained at pH 6.7, 28℃, 2.5 slpm
aeration, and 350 rpm stirring. Consumption of carbohydrates during growth was
measured on a Shimadzu LC-10 HPLC system (Shimadzu, Columbia, MD) equipped
with 802 BP-100 H+ column (300×7.8 mm, Benson Polymeric Inc., Sparks, NV) and a
low temperature evaporative scattering detector ELSD-LTII (Shimadzu, Columbia, MD),
using deionized water at a flow rate of 0.4 mL·min -1 as mobile phase (Zhao et al. 2013).
At 40 h after inoculating the bioreactor, SRE was only detected (by HPLC) in the foam
that accumulated above the culture medium and not in the culture broth. SRE was
collected by siphoning the foam material.
Organic-compatible SRE purification
Formic acid and isopropanol, both on the National List of Allowed and Prohibited
Substances (USDA 2015), were selected as solvents for large-scale preparative
purification of SRE. Formic acid was added to the collected foam at a concentration of
0.1% (v·v-1), and the solution was centrifuged at 4000×g for 60 min to remove cell
debris. The supernatant was adjusted to pH 3.5 and subjected to an ÄKTA avant 150
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Liquid Chromatography System (GE Healthcare Life Sciences, Piscataway, NJ) equipped
with a 6.4×100 mm ResourceTM RPC C18 column (GE Healthcare Life Sciences,
Piscataway, NJ). The gradient elution of SRE was performed using solvent A: 0.1% (v·v 1

) formic acid in water and solvent B: 0.1% (v·v -1) formic acid in isopropanol at a flow

rate of 2.2 mL·min-1 with the following program: 0-20% solvent B, 3 min; 20-45%
solvent B, 42 min. The elution was monitored at 240 nm and fractions were collected
separately every 1 min. HPLC fractions eluting with 29-30% solvent B were determined
to be SRE based on co-elution with a SRE standard. Purified SRE was lyophilized and
stored at ‒20℃. A sample of the purified material was sent to the Proteomics and

Metabolomics Facility, Colorado State University (Fort Collins, CO) for MALDI-TOF
analysis.
SRE quantification
Cultures or SRE preparations were extracted in 50% (v·v-1) acetone in water
acidified with 0.4% (v·v-1) HCl. The extract was diluted with water to make a final
concentration of 25% (v·v-1) acidified acetone in water and loaded on a C18 Resprep®
SPE cartridge (Restek. Co., Bellefonte, PA). The cartridge was washed with 25% (v·v -1)
acidified acetone in water, and SRE was eluted with 100% acidified acetone. The eluent
was dried under a stream of air and suspended in 60% (v·v -1) acidified acetone in water
for HPLC analysis. The prepared sample was loaded on a 100×4.60 mm GEMINI-NX
C18 column (Phenomenex Inc., Torrance, CA). The elution gradient of solvent A: 0.1%
(v·v-1) trifluoroacetic acid (TFA) in water and solvent B: 0.1% (v·v -1) TFA in isopropanol
was 30% solvent B, 2 min; 30-80% solvent B, 15 min; 80-100% solvent B, 1min; 100%
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solvent B, 1 min with a flow rate of 0.5 mL·min -1 on a Beckman System Gold RP-HPLC
instrument (Beckman Coulter, Inc., Brea, CA). Absorbance was monitored at 240 nm.
The amount of SRE was quantified by comparisons to a standard curve constructed with
known amounts of SRE produced by the conventional method (Bidwai and Takemoto
1987; Zhang and Takemoto 1987).
Activity test of SRE against P. ultimum
oospores
P. ultimum was grown in 12 mL of V8-cholesterol broth (Ayers and Lumsden
1975) in sterile petri dishes incubated in the dark at room temperature without shaking for
3 days. Mycelial mats which formed in the petri dishes were rinsed two times with sterile
mineral solution (0.9 mM Ca(NO3)2, 0.1 mM MgSO4, 0.7 mM KH2PO4, and 0.1 mM
FeCl3) and then incubated in sterile petri dishes filled with 12 mL sterile distilled water in
the dark at room temperature for 7 days. Oospores formed in mycelial mats were
harvested using a Dounce glass homogenizer followed by filtration through glass fibers to
remove mycelial fragments. The oospore concentration was estimated with a
hemocytometer. Oospores at a concentration of 10 5 oospores·mL-1 were incubated in
PDB containing 0, 3.9, 15.6, 31.3, 62.5, 125, and 250 µg·mL-1 of SRE or 0/0, 3.9/11.7,
15.6/46.8, 31.3/93.9, 62.5/187.5, 125/375, and 250/750 µg·mL -1 of SYRA (SRE/RL) in a
96-well plate. Rhamnolipid (RL, Zonix TM, Jeneil Biosurfactant Co., Saukville, WI), a
commercial organic-compatible fungicide, was also tested at concentrations of 0, 11.7,
46.8, 93.9, 187.5, 375, and 750 µg·mL-1. Oospore germination was observed with light
microscopy after 4 h incubation at 24℃.
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Soil drench application of SRE on
cucumber seeds
The effect of SRE as an agrofungicide was tested on organic cucumber seeds
(Snow Seed Organic, Salinas, CA) and against P. ultimum infection. Cucumber seeds
were planted in 24-well plates with Sunshine Mix 4 potting medium (Sun Gro
Horticulture Inc., Bellevue, WA) artificially infested with 0 or 500 P. ultimum
oospores·g-1 (Cummings, Miles, and du Toit 2009). The potting medium was drenched
with 4 mL·g-1 of sterile distilled water, 50 µg·mL-1 SRE, or 500 ppm RL. Each treatment
was composed of 24 planted seeds. Germination and growth of cucumber seedlings were
observed with incubation at 25℃ with 12 h light and12 h dark for 6 days in a growth
chamber (Percival Scientific Inc., Perry, IA). The averages of germination rates and
standard errors were calculated based on three repeats of experiments.
Coating application of SRE on cucumber seeds
Non-treated organic cucumber seeds (Snowseed Co., Salinas, CA) were dipped
into 0.3 mg·mL-1 SRE in 5% heat-gelatinized starch and dried at 4℃. Eight of each noncoated and SRE-coated seeds were planted on 1.5% water agar to test effects of SRE on
seeds. Then eight seeds of non-coated and SRE-coated cucumber seeds were placed in
petri dishes filled with soil naturally infested by P. ultimum collected at the Utah State
University Research Farm (Kaysville, UT). Seeds were incubated at 25℃ in the dark for
6 days and the emerging seedlings were counted. The experiment was repeated three
times and germination rates and standard errors were calculated. To confirm the cause of
disease in naturally infected soil, non-germinated cucumber seeds were plated on 1.5%
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water agar after surface sterilization by soaking in 20% bleach for 30 s and rinsing with
sterile water. The growth on water agar was observed under microscope. The occurrence
of Pythium was verified by PCR using the following methods: DNA was extracted from
the recovered Pythium mycelial mats using the FastDNA Spin kit (MP Biomedical, Santa
Ana, CA, USA) and following the manufacturer’s protocol. The universal fungal primers
for the internal transcribed spacer (ITS) region, ITS 4 and ITS 5 (White et al. 1990), were
used for PCR. PCR reactions consisted of 5 µL 10× PCR buffer, 5 µL Q solution, 1 µL
dNTPs (Qiagen Inc., Valencia, CA, USA), 1 µL primer ITS 4 (100 pmol), 1 µL primer
ITS 5 (100 pmol), 2 µL DNA and 0.25 µL Taq DNA polymerase. Nuclease free water
was added to obtain a 50 µL final volume. The reaction was denatured at 95℃ for 3 min,
followed by 35 cycles of 95℃ for 1 min, 52℃ for 1 min, 72℃ for 1 min, and a final
extension for 10 min at 72℃. The PCR products were visualized in a 1% agarose gel
stained with ethidium bromide. The resulting bands were cut out and the DNA extracted
using QIAquick Gel Extraction Kit (Qiagen Inc., Valencia, CA) following the
manufacturer’s protocol, and sequenced at the University of Arizona Genetics Core
facility (Tucson, AZ). The sequences were compared to other fungal sequences in the
NCBI GenBank® database using the BLAST search function for species identification
Phytotoxicity test of SRE on carrot, hot
pepper, lettuce, and tomato seeds
Non-treated organic seeds of carrot, hot pepper, and lettuce (all from Burpee
Garden Products Co., Warminster, PA, USA), and tomato (Territorial Seed Co., Cottage
Grove, OR, USA) were coated with SRE in heat-gelatinized starch as described above.
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Eight of each non-coated and SRE-coated seeds (carrot, hot pepper, lettuce, and tomato)
were planted on 1.5% water agar to test phytotoxicity of SRE on different vegetable
seeds.
Results
Novel SRE-producing P. syringae pv.
syringae strains and growth medium
development
P. syringae pv. syringae strain 2B6 cultures had the highest antifungal activities
when grown in modified SRM containing 1% (w·v-1) glucose and 1% (w·v-1) mannitol
(ISM) compared with activities observed with substitution of other carbon sources and
compounds for glucose (Table 4-1). With ISM, P. syringae pv. syringae strain G10
(derived from P. syringae pv. syringae strain 2B6) produced 53 mg·L-1 SRE, which is
>35% higher than strain B301D (37-39 mg·L-1) produced in agitated flask cultures (Table
4-2). The level of SRE production under these conditions was not improved with the
addition of 100 μM arbutin plus 0.1% (w v -1) fructose to the growth medium, a
combination previously shown to stimulate SRE production by strain B301D in SRM
(Mo and Gross 1991).
Scalable SRE production
In an agitated and aerated 10 L capacity WinPact bioreactor and with ISM as
growth medium, P. syringae pv. syringae strain G10 grew and produced foam on the
culture surface. At the end of the bioreactor culture period at 40 h, 5 g·L -1 of glucose
remained, while the mannitol concentration remained steady between 9 and 10 g·L -1

88
throughout the culture period (Fig. 4-1). The bioreactor culture began to foam on the
liquid surface between 15-30 h coincident with initial detection of SRE in the culture
broth (at 0.036-0.06 mg·L-1 SRE). At 40 h, SRE product was detected in the foam above
the culture broth but not in the culture broth. The foam containing accumulated SRE was
collected by siphoning. The SRE yield averaged 50 mg·L-1 of culture.
SRE purification
The collected foam material (in liquid form) was adjusted to pH 3.5 with formic
acid. It was then subjected to one-step C18 reverse phase chromatography.
Approximately 75% of the SRE activity applied to the column was recovered in material
eluting as a single chromatographic peak (Fig. 4-2). MALDI-TOF analysis of the sample
showed a molar mass of 1225 Da (Fig. 4-3), the expected value for SRE (Monti et al.
2001).
Activity of organic-compatible SRE
against P. ultimum oospores
P. ultimum oospores were exposed to different concentrations of SRE, SYRA and
RL, and germination rates were determined (Fig. 4-4). SRE prevented 50 and 90% of the
oospores at 31.3 and 250 µg·mL-1 SRE, respectively. On the other hand, there were no
significant differences between germination rates of non-treated and SYRA-treated
oospores. RL-treated oospores also exhibited no inhibition of germination, though RL
treatment did result in an increase in the appearance of tangled and branched germ tubes
(Fig. 4-4).
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Soil drench application of SRE on
cucumber seeds
The germination of cucumber seed was counted after 6 days from soil drench
treatment with water, SRE, and RL treatments. With water soil drench treatment, the
germination rates of cucumber seeds were 82.0±5.2% (mean±standard error) and
65.7±4.6% in non-infested and infested potting medium, respectively. Drench treatment
of SRE had a 93.3±2.3% germination rate in non-infested medium and a 90.2±4.5%
germination rate in infested medium. There were no significant disease symptoms
compared to the control water-treatment in non-infested potting medium. Pre-emergence
Pythium damping-off disease incidence was prevented by soil drench treatment with 50
µg·mL-1 SRE. The treatment with 500 µg·mL-1 RL resulted in germination rates of
44.7±2.3% with oospores and 79.0±4.0% without oospores. RL did not inhibit P.
ultimum oospore germination or mycelial infection on cucumber seedlings.
Coating application of SRE on cucumber
seeds
SRE was coated on cucumber seeds at a level of 0.03% (w·w -1). There was no
significant difference between germination rates of non-coated (95.8±4.2%) and SREcoated (95.8±4.2%) cucumber seeds. SRE-coated cucumber seeds sprouted at the rate of
76.1±11.5% on naturally infested soil, while non-coated seeds had a germination rate of
0.0±0.0%.

Coenocytic hyphae were grown from surface sterilized non-germinated

cucumber seeds on water agar plates after 24 h incubation at room temperature. Gene
sequence analysis (18S rRNA) identified these isolates as P. ultimum var. ultimum (Fig. 45). SRE decreased Pythium damping-off onsets of cucumber seeds.
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Phytotoxicity test of SRE on carrot, hot
pepper, lettuce, and tomato seeds
The amount of SRE applied on carrot, hot pepper, lettuce, and tomato seeds were
estimated as 0.12%, 0.09%, 0.07%, and 0.28% (w·w -1), respectively. There was no
significant difference between germination rates of non-coated seeds and SRE-coated
seeds on water agar (Table 4-3), thus 0.03% to 0.28% (w·w -1) SRE was not phytotoxic to
seeds.
Discussion
In this work, scalable methods for SRE production and purification were designed
to meet USDA organic standards (USDA 2015). The combination of using a revised
growth medium (ISM), novel production method, and cultivation of P. syringae pv.
syringae strain G10 in a bioreactor grown with aeration and agitation resulted in a greater
yield of SRE (50-53 mg·L-1) than previously reported (~15 mg·L-1) (Gross 1985; Gross
and DeVay 1977a; Mo and Gross 1991; Surico, Lavermicocca, and Iacobellis 1989;
Zhang and Takemoto 1987). The inclusion of mannitol in the medium was key to
increased yields of SRE in agitated cultures (Table 4-1), though it was not consumed
during the growth of P. syringae (Fig. 4-2). Mannitol has been shown to alter the
physiology of some bacteria. As an example, mannitol increases the antibiotic sensitivity
of persisters in P. aeruginosa biofilms due to a combination of metabolic and osmotic
changes (Barraud et al. 2013). Further research is necessary to discern the role of
mannitol in the increased production of SRE by P. syringae pv. syringae.
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The aerated bioreactor culture used in this study permitted the partitioning and
recovery of the SRE produced in foam that accumulated at and above the surface of the
culture. This eliminated the need to separate and extract SRE away from cells and
cellular debris which greatly facilitated its purification. A previously used and common
SRE purification method required several days and involved culture extraction with
solvents followed by Amberlite XAD-2 chromatography and HPLC using a C18 silica
reverse phase column (Bidwai et al. 1987). In contrast, the currently described method
involves extraction of the foam material and single step chromatographic purification
through an ÄKTA avant 150 Chromatography System yielding purified SRE within a few
hours. Also, the new purification process employs isopropanol and formic acid instead of
acetone, methanol, and TFA (Bidwai et al. 1987). Isopropanol and formic acid are listed
as “allowed” on the National List of Allowed and Prohibited Substances (USDA 2015)
that will contribute to its consideration as an organic-compatible fungicide. Scalable
production of an organic-compatible SRE product could help to meet the growing
demand for effective fungicides in organic farming.
The product SRE inhibited germination of oospores, the major primary infection
source in epidemics of Pythium damping-off disease. Most fungicides available in the
market such as RL have little or no effect against Pythium oospores (Stasz and Martin
1988), and this lack of inhibitory effect was confirmed in the current study with Pythium
oospores (Fig. 4-4). In contrast, SRE’s observed inhibitory activity against Pythium
oospores offers the possibility for the control of damping-off disease. Soil drench and
seed treatment with organic-compatible SRE inhibited P. ultimum infection during early
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development of cucumber seedlings. In contrast, SYRA, which is a mixture of SRE and
RLs, did not inhibit oospore germination. Although RLs are reported to enhance the
antifungal activity of SRE against several fungal pathogens of grape (Takemoto et al.
2010), it reduced SRE’s inhibitory activity against P. ultimum oospores (Fig. 4-4).
Thick-walled oospores are usually insensitive to fungicides (Stasz and Martin 1988).
Zoosporic stages are susceptible to inhibition by RLs (Kim, Lee, and Hwang 2000; Maier
and Soberón-Chávez 2000), but P. ultimum var. ultimum rarely produces sporangia and
zoospores (Levesque et al. 2010).
On water agar no significant difference was observed between the germination
rates of non-coated and SRE-coated seeds, and SRE did not stunt cucumber seedlings.
These findings support accumulating evidence that SRE and similar cyclic
lipononapeptides are not phytotoxic (Bull et al. 1997, 1998; Mendes et al. 2011;
Pauwelyn et al. 2013; Williamson et al. 2008) despite their historic portrayal as
phytotoxins (Bidwai and Takemoto 1987; Gross and DeVay 1977b; Iacobellis et al. 1992;
Kauss et al. 1991). The syringomycins were originally described as antibiotic
compounds against fungi and yeasts (Sinden et al. 1971). Structurally related cyclic
depsipeptide compounds, principally syringopeptins, are biosynthetically produced
simultaneously with the syringomycins by P. syringae pv. syringae (Ballio et al. 1991,
1994). The latter are more antibacterial and phytotoxic and less antifungal than the
syringomycins (Bensaci et al. 2011). With impure cell extracts, the phytoxic properties of
syringopeptins may be erroneously attributed to syringomycins. The relative amounts of
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the syringomycins and syringopeptins likely influence the complex balance between the
pathogenic and saprophytic life styles of P. syringae pv. syringae.
Antifungal but non-phytotoxic property of SRE predict that it is a candidate
fungicide for use in organic farming. SRE is water soluble and physically stable up to
121℃, with UV light exposure, and at pHs below 8. Its shelf life is sufficient and
comparable to most commercial fungicides. Importantly, SRE is not toxic to animals at
concentrations at which it is fungicidal (Sorensen et al. 1998; Fiore et al. 2008) and
despite being hemolytic (Sorensen, Kim, and Takemoto 1996). Formulated nonpathogenic SRE-producing strains of P. syringae pv. syringae (ESC10 and ESC11) are
approved by the US Environmental Protection Agency for use as post harvest biological
decay control agents (Bull, Stack, and Smilanick 1997; Bull et al. 1998).
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Table 4-1 Influence of carbon compounds substituted for 1% glucose in SRM growth
medium on antifungal activity of SRE-producing P. syringae pv. syringae strain 2B6.
Glucose substitutes (1%, w·v-1)
none
glycerol
ribose
galactose
mannitol
lactic acid
acetate
succinate
glucose plus mannitol
2× glucose plus 2× mannitol

glucose plus 100 µM arbutin and 0.1 % (w·v-1) fructose

glucose plus100 µM salicylate and 0.1 % (w·v-1) fructose

Antifungal activity
++
+
+
+
+++
++
++
+
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Table 4-2 Influence of growth medium composition on SRE production by P. syringae
pv. syringae strain G10 in agitated flask cultures
Growth medium
SRM
ISM
SRM plus 100 µM arbutin and 0.1% (w·v-1) fructose
ISM plus 100 µM arbutin and 0.1% (w·v-1) fructose
SRM plus 100 µM salicylate and 0.1% (w·v-1) fructose

SRE yield (mg·L-1)
14
53
28
51
16
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Table 4-3 Germination rates of non-coated and SRE-coated seeds on water agar and
naturally infested soil

water agar
carrot
hot pepper
lettuce
tomato
cucumber
infested soil
cucumber

Germination rates (%)
non-treated
SRE-treated
79.2±8.3
87.5±0.0
95.8±4.2
92.7±4.2
95.8±4.2

87.5±7.2
87.5±7.2
100.0±0.0
91.7±4.2
95.8±4.2

0.0±0.0

76.1±5.1
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Fig. 4-1 P. syringae pv. syringae strain G10 growing in ISM in a Winpact Bioreactor
and Fermenter system with aeration and agitation produces SRE (×) and consumes
glucose (). Mannitol () is not consumed during growth.
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Fig. 4-2 Chromatographic profile of a SRE extract using an ÄKTA avant 150
chromatography system. The solid line shows the 240 nm absorbance (A) profile and the
dotted line the percentage of solvent B (0.1% formic acid in isopropanol) in solvent A
(0.1% formic acid in water). The peak at 17.7 min is designated with an arrow and
identified as SRE using HPLC.
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Fig. 4-3 MALDI-TOF mass spectrum of the HPLC purified SRE material produced by
P. syringae pv. syringae strain G10. The major ion detected at m/z = 1225.482 identified
it as SRE.
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Fig. 4-4 Oospore germination test. Germination rates of P. ultimum oospores were
counted in PDB containing different concentrations of SRE (A-1), SYRA (B-1), and RL
(C-1). Photographs (right panels) showing non-treated oospores and oospores treated
with 250 µg·mL-1 SRE (A-2), 250/750 µg·mL-1 (SRE/RL) SYRA (B-2), 750 µg·mL-1 RL
(C-2) treated oospores and non-treated (D) oospores were taken after 4 h incubation.
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GGTCC-ATTGAGATACCATACACAATCTTGCAATTGACAATGATACAAAATTTCCCAAAT
CAATCTCTCTACGCAACTAAATGCAGCGTCTCCATACATCGTGAAAATGCTCTACTAAAC
AATCACTTACGGTTCAAACCGACAACCTCTAGTACACCTCAAGGCACAAACAAAGACCAC
ACACAATTACGCAACATTGTCGAGCCGAAGCCTAACATACCACGAATTGAGCTAGTCTCC
ATACGTTCATACCGAAGTCGCCAAAAGCCGCCAGCAATCCGAAAATCACTGCCTTCCAAC
CATTACACTTCATAGAAACCATAGAAAAGACCGTGTCCATTTAAAAGGACTCGACAGATT
CTCGATCGAAAAAACGAACGCAACCATGCGAGACACTTCACATCTGCACATTCCATCCCT
GACTACACAGAAAAAGAAAGGCAAGTTTGATTTACGGACACTGATACAGACATACTTCCA
GGCATAACCCGAAAGTGCAATATGCGTTCAAAATTTCGATGACTCACTGAATTCTGCAAT
TCGCATTACGTATCGCAGTTCGCAGCGTTCTTCATCGATGTGCGAGCCTAGACATCCACT
GCTGAAAGTTGTTATCTAGTAAAAGCAAGGACTTTCGTCCCCACAGTATAAATCAGTATT
TAGGTAAGGGTTTAAAAACAAAAGTTCATCAGCTAGTCCATCATAACTTGCATTACAACA
GACCAACCTTCGTCCTGCTGACTCCCGTTCCAGTGTCCAAAAATGAAAACACCAGCTCAG
TCCCAGCGCTAGACTGGCTTACAGTTCACGTGGACAGTTTTTTNAAGTGTGGTAATGATC
CTTCCGCAGGTTCACCTACGGNAACCTTGTTACG-CTT

Fig. 4-5 DNA nucleotide sequence of the mycelial growth recovered from a cucumber
seed planted in naturally infested soil. The sequence matches (highlighted, 99%
identities) the partial sequence of the 18S ribosomal RNA gene of P. ultimum var.
ultimum in the NCBI database.
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CHAPTER 5
SUMMARY AND FUTURE DIRECTIONS
Bacteria inhabit all ecological niches of the Earth and therefore they produce
diverse bioactive metabolites as their survival tools for stress tolerances and interactions
with other organisms. However, microbes often produce these valuable metabolites in
tiny amounts just enough to satisfy their own needs. Recent advanced techniques in
molecular biology, biological engineering, metabolic engineering, organic chemistry and
other related fields of study focus on microorganisms as sources of natural products.
Application of biological manipulations in bacteria and rapidly-growing unicellular
organisms contribute to large-scale productions of natural products (3, 10). The aims of
this study were scalable productions of two different natural products, potent
cytoprotectant biliverdin IXα and potential organic-compatible agrofungicide
syringomycin E (SRE) in Escherichia coli and Pseudomonas syringae pv. syringae,
respectively.
Current commercially available biliverdin IXα is prepared by chemical oxidation
of bilirubin IXα extracted from animal bile (6). This chemical process generates
significant levels of biliverdin IIIα and XIIIα, and removal of these non-bioactive isomers
is difficult (5, 7). In this study, biliverdin IXα production was conducted by gene
recombination and fed-batch fermentation. A recombinant E. coli strain BL21(mHO1GFP) transformed with a sequence-modified cyanobacterial heme oxygenase-1 (mho1)
gene was reported to solely produce biliverdin IXα isomer (1). Enzymatic activity of HO
is strongly dependent on electron donors and the electron flow from NADPH to
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heterogeneous HO is considered to be NADPH → NADPH‒flavodoxin/ferredoxin
reductase (FNR) → flavodoxin (Fld) → mHO1 in recombinant E. coli. FNR and Fld
were plasmid-overexpressed in E. coli strain BL21(mHO1-GFP) and two new strains
BL21(mHO1-GFP+FNR) and BL21(mHO1-GFP+Fld) were obtained, respectively. The
construct BL21(mHO1-GFP+Fld) yielded 17-40% more biliverdin IXα comparing to the
strain BL21(mHO1-GFP) whereas BL21(mHO1-GFP+FNR) did not improve the yield.
In addition, BL21(mHO1-GFP+Fld) achieved 13-26% higher cell density than
BL21(mHO1-GFP) at the end of biliverdin IXα production growth. Overexpression of
Fld in E. coli had been reported to confer resistance against oxidative stress (2). Further
study will be required to clarify the mechanism how Fld contributes in high cell density
cultivation of E. coli.
On the other hand, an enhanced SRE producer strain of P. syringae pv. syringae,
G10, was isolated via UV radiation mutagenesis without artificial genetic modification to
meet the USDA organic standards (8, 12). While SRE production in the past was done in
still batch cultures, the strain G10 reported in this dissertation research allowed SRE
production in agitated conditions. As a result of strain development, medium
modification, and agitated growth conditions, SRE yield increased from 10-20 mg·l -1 to
50 mg·l-1 and the production period was shortened from 10 days to 40 h compared the
conventional methods (4, 13). Then, SRE purification protocol was also improved from
µg-levels to mg-levels with employment of a large scale chromatography system and
organic-compatible solvents. The purified product SRE was examined as a seed
protectant against a soil-borne pathogen P. ultimum. SRE suppressed germination of
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oosporic P. ultimum which is resistant to fungicides (11). SRE (0.03% w·w -1) - and noncoated vegetable seeds had the same germination rates under pathogen free environment
while SRE-coated seed had higher germination rates in infested media. SRE behaved as
a potential organic-compatible seed protectant.
Optimization of medium components was performed for the production of both
biliverdin IXα and SRE. Different carbon sources were tested in media to maximize the
yields. In the recombinant strain of E. coli, lactose was the key to induce heterogeneous
mHO1 protein expression, whereas glycerol was the important factor for high cell density
cultivation. In UV-mutated P. syringae pv. syringae, inclusion of mannitol in the culture
medium facilitated SRE production under agitated conditions, while mannitol was not
consumed throughout the fermentation period. Different carbon sources affect different
levels of cell activities in different ways. Optimization of carbon sources is an essential
process to increase yields of the desired metabolites.
In general industrial fermentation, foam causes undesirable consequences,
reduced oxygen transfer rates, losses of fermentation culture, and contamination of
culture by wetting the air filters (9). However, in this dissertation study, foam was
desired for the separation of the products in fermenter systems. Foam formation was
observed during biliverdin IXα and SRE production and the products were accumulated
in the foam above the culture but not in the culture broth. The products were collected by
siphoning foam materials, and foam floatation greatly facilitated extraction of products.
In fed-batch production of biliverdin IXα, glycerol feed was used to boost biliverdin IXα
production while the product was constantly removed from the fermenter system as foam.
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Further growth optimization could be done to make continuous culture systems for
extended production phases and thus enhanced yields.
In conclusion, bacteria are small organisms but have huge potentials to synthesize
high-value bioactive compounds. scalable production methods of biliverdin IXα and
SRE were proved through strain development and fermentative growth of the resulting
strains. Gene recombination and mutation were performed to achieve overproduction of
the desired metabolites in bacteria. Growth parameters were modified to maximize the
yields in fermenters. Despite the fact that production of biliverdin IXα and SRE was
enhanced, there is ample scope for further improvement. For instance, additional
manipulation of growth parameters may further enhance yields.
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